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Abstract
N-acyl-7-nitroindolines are photoreactive compounds that are known to acylate a number
of nucleophiles in inert aprotic solvents under neutral conditions when illuminated at 350 nm.
We have assembled a MUC1-derived peptide and Tn or STn-containing MUC1 glycopeptides
with a C-terminal photoreactive 7-nitroindoline linker attached to Sieber amide resin by solid
phase peptide synthesis using the Fmoc strategy. This type of construction allows for the
cleavage of fully protected photoreactive peptides/glycopeptides from the resin with dilute
trifluoroacetic acid, or for the direct photorelease of protected peptide/glycopeptide derivatives.
Here we demonstrate that N-peptidyl and N-glycopeptidyl 7-nitrindolines can be
photochemically converted into their peptide acids, activated esters, amides, or thioesters when
illuminated with near UV light in the presence of an appropriate nucleophile (H2O, HOBt,
RNH2, or HOSu followed by RSH) thus demonstrating the chemical versatility of N-peptidyl-7nitroindolines.
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Chapter 1: Introduction

1.1 Solid Phase Peptide Synthesis
Over the last decade there has been a huge increase in interest towards peptide and
glycopeptide research, mainly due to their therapeutical potential. Peptide therapeutics have
expanded almost twice as fast compared to other drug therapeutics1. There are currently 70
peptide drugs approved by the FDA which have reached the medicinal market2, as well as over
150 peptides currently in clinical trial and over 400 peptides in advanced preclinical trials3.
This increase in peptide therapeutics can be attributed to the biological activity of target
peptides as active hormones, growth factors, antibiotics, signaling molecules, neurotransmitters
and neuropeptides. Due to a fast development in genomics, proteomics and transcriptomics over
the last decade, a large number of target peptides and proteins have emerged4. Thanks to this
rapid development in technologies, peptides are being used to treat diseases such as cancer,
osteoporosis, and cardiovascular diseases5.
Peptides, when compared to smaller synthetic drugs, tend to have strong and specific
binding to their molecular targets, which generally translates to a reduced drug dose. This high
selectivity, which they share with proteins, also leads to fewer side effects, which tend to plague
small molecules1, 3. Not only do they share these benefits with proteins, but they are smaller and
easier to synthesize, making them in principle an ideal target for drug design5b. However, due to
their short laft lives, their bioavailability is generally poor. Therefore, medicinal chemistry
focuses on peptide mimetics that cannot be quickly metabolized by enzymes.
The term “peptide” was coined by Emil Fischer after his successful synthesis of the
dipeptide glycylglycin in 19016. From here, future peptides were synthesized utilizing a method
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now coined as solution phase synthesis (SPS), wherein the carboxyl group of amino acid 1 and
the amino group of amino acid 2 are blocked, and activation of the carboxyl group of amino acid
2 results in a native amide bond between the two amino acids. The peptides then have to be
purified and characterized before the next coupling step, resulting in an incredibly laborious
method for peptide synthesis when larger peptides are desired7. Not only is SPS time consuming,
it also has other downfalls such as peptide insolubility of longer sequences8 and lower yields due
to continuous chromatography and crystallization steps9.
These disadvantages were completely eradicated by Bruce Merrifield in 1963 following
his successful synthesis of the tetrapeptide Leu-Ala-Gly-Val10 by what is now called Solid Phase
Peptide Synthesis (SPPS). This method utilizes an insoluble solid support (such as the Merrifield
resin composed of chloromethylated polystyrene crosslinked with 1-2% divinylbenzene) which
anchors the growing peptide at its C-terminus. This resin is then used to “hold” the growing
peptide in place. The amino acids used for SPPS have a free C-terminus, a protected N terminus
(usually Boc of Fmoc), and an orthogonally protected side chain. Side chains will be discussed
later in this chapter. The C-terminus is then activated with a coupling reagent, forming an
activated ester with an auxiliary nucleophile which then undergoes nucleophilic acyl substitution
with the unprotected N-terminus of the growing peptide chain, thus forming a native amide bond.
The growing peptide is then capped to prevent unreacted amines from further reacting with
subsequent activated amino acids. The N-terminus is then deprotected and the previous steps are
repeated until the desired peptide sequence is achieved (Scheme 1).

2

deprotection

1) PG-AA-OH, coupling reagents
2) Capping

PG: Protecting Group (Boc,
Fmoc)
SPG: Side Chain Protecting
Group (OtBu, Trt, etc…)

Nα deprotection

1) Cleavage
2) Side chain
deprotection

End of
elongation

Scheme 1: SPPS using an amine resin such as Rink or Sieber amide resin.
SPPS offers several key improvements over SPS. Byproducts and unreacted starting
materials are simply filtered out, thus eliminating purification steps entirely until the peptide is
cleaved from the solid support. Second, insolubility of longer peptides is no longer an issue, as
the whole peptide is now attached to an already insoluble solid support. However, aggregation
can occur which results in poor yields. Third, due to the simplicity and recurrent steps found in
SPPS, it is a perfect candidate for automation. Indeed, most SPPS is carried out by automated
peptide synthesizers3, 8, 11.
Despite its advantages over SPS, SPPS is not without faults12. One of the major problems
of SPPS is the large amounts of amino acid and coupling reagents needed for the coupling
reaction. Standard coupling conditions13 generally dictate the use of 5 equiv. each of amino acid,
auxiliary nucleophile, and activating agent, as well as 10 equiv. of base. Even with large excess,
double and triple coupling may be required. This can result in quite a large monetary burden,
especially if the amino acids used are considered special (i.e. glycosylated) or uncommon (i.e. D3

amino acids). Another possible problem with SPPS is the compatibility, or lack thereof, between
protecting groups and current solid supports. Depending on the protecting groups used, the resin
utilized, and the end goal for the peptide, incompatibilities in peptide synthesis could arise
between these three parameters. Also, due to the lack of purification during SPPS (which was
viewed as an advantage earlier), the end product could contain several smaller failed sequences
which could be quite problematic during the purification process after cleavage.
As mentioned previously, peptides built through SPPS are anchored through the amino
acids C-terminus and elongated along the N-terminus. This allows for the C-terminus to be
deprotected, but requires the protection of both the N-terminus as well as any reactive side chain
functional groups. The two most common strategies for Nα and side chain protection are Boc/Bn
and Fmoc/tBu (Figure 1).
The Boc (Nα protection) and Bn (side chain protection) strategy is based on graded acid
lability of the protecting groups. After coupling, the N-terminus is deprotected by using TFA.
After peptide elongation, the peptide is simultaneously cleaved and fully deprotected through the
use of HF 14 (Figure 1A). The use of highly toxic HF requires the use of polytetrafluoroethylenelined vessels, limiting the ease-of-use of this method. Moreover, the repeated TFA exposure
during Boc deprotection can lead to acid-catalyzed side reactions15. In addition, due to the lack
of orthogonality, the use of this Boc/Bn strategy always leads to deprotected peptides. Therefore,
this method is not suitable when a protected peptide is required for further modifications. Despite
its limitations, Boc strategy can still be useful for the synthesis of long and/or difficult peptide
sequences due to minimized aggregation resulting from repetitive exposure to TFA16. This
strategy was first introduced by Merrifield and is still in use today, although to a much lesser
extent.
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The alternative to the Boc/Bn strategy is the Fmoc (for Nα protection) and tBu (for side
chain protection) strategy, which was introduced by Caprino in 197017 (Figure 1B). The base
sensitive Fmoc groupis being used as a temporary protecting group, and acid-sensitive protecting
groups (mostly tBu and trityl groups) are used as “permanent” protecting groups for the side
chains.18. The Fmoc group and the side chain protecting groups are completely orthogonal.
Unlike the Boc strategy, the Fmoc strategy does not suffer from acid-induced side reactions. By
using the right resin one can cleave the peptide without deprotecting the N-terminus or side chain
protecting groups, or deprotect a specific orthogonal site without affecting other groups and/or
the resin linkage. Nowadays the Fmoc strategy is by far the most widely utilized method for
SPPS, and most resins and protecting groups tend to be tailored towards use under Fmoc peptide
strategy.

A

Fmoc

B
TFA

Boc

HF

piperidine

TFA

TFA
HF

tBu

Bn

Figure 1: (A) Boc/Bn and (B) Fmoc/tBu protecting group strategies for SPPS.
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In the Fmoc strategy, all of the protecting groups utilized on the side chains of amino
acids are acid labile. The two most common protecting groups used for amino acid side chains
are trityl (Trt) and tert-Butyl (tBu); lysine and tryptophan are generally protected with Boc, and
arginine is usually protected with pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl (Pbf) on the
side chain. What all of these protecting groups share is that they are all acid labile and are
completely removed with neat TFA.
For decades the major coupling reagents used for activation of the carboxylic acid during
SPPS were N,N’dicyclohexylcarbodiimide (DCC) and N,N’-diisopropylcarbodiimide (DIC)19. It
was later found that carboxylic acids activated with these carbodiimide derivatives were highly
prone to racemization. It was at this point that racemization suppressants began to be used, such
as 1-hydroxy-benzotriazole (HOBt)20. These racemization suppressants, now called auxiliary
nucleophiles because of their nucleophilic role during SPPS, are now considered essential in
SPPS. Amongst the most commonly used auxiliary nucleophiles are HOBt and 1-hydroxy-7azabenzotriazole (HOAt)18a. Along with these auxiliary nucleophiles, new coupling reagents
began to emerge to replace the racemization-inducing carbodiimides. Top amongst these new
coupling reagents are N,N,N’,N’-tetramethyl-O-(1H-benzotriazol-1-yl)uranium
hexafluorophosphate (HBTu), (N-[(1H-benzotriazol-1-yl)(dimethylamino)methylene]-Nmethylmethanaminium tetrafluoroborate-N-oxide (TBTU)21, and (N-[(dimethylamino)-1H-1,2,3triazolo-[4,5-b]pyridine-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate-N-oxide
(HATu)22.
The last major component of SPPS, and perhaps the most important one, is the solid
support used. Today there is a plethora of choices when it comes to solid support resins, each
having their advantages and disadvantages over the others. Most resins fall into three categories:
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the more traditional polystyrene (PS) resins, polyethylene glycol (PEG) functionalized PS12b, and
pure PEG resins23. From here, resins deviate from each other depending on the type of linker
they carry; this linker provides the anchor between the peptide and the solid support and dictates
the functionality of the C-terminus at the end of SPPS. The two most common functionalities for
the C-terminus at the end of SPPS are carboxylic acids and amides. However, other
functionalities can be accomplished, such as hydrazides and thioesters24. There are also resins
(such as 2-chlorotrityl25 and Sieber amide26) which allow cleavage with very dilute TFA
concentrations, allowing for the cleavage of protected peptides.
Our project involves the use of N-acyl-7-nitroindoline as a photoreactive linker for use in
Fmoc-based SPPS. As mentioned above, most resins yield either free acids or amides on the Cterminus of a peptide after cleavage. Our nitroindoline linker is much more versatile, and has the
capacity of yielding many more C-terminal derivatives through exposure to 350 nm light, a
method which is unobtrusive and does not affect the peptide or its protecting
groups/glycosylations. To showcase the versatility of our photoreactive nitroindoline linker we
have decided to use a 13 amino acid sequence from the tandem repeat sequence of MUC1. We
have chosen to photochemically form the free acid, as well as acylating a Biotin-containing
amine linker for possible binding to (strept)avidin immobilized surfaces, and forming thioesters
for possible use in Native Chemical Ligation. We have also used glycopeptides to show that the
photoacylation reactions work with sensitive glycosylations (Tn and STn antigens) present.
Thioesterificatin of these glycopeptides is of special interest to our group. Due to a high tendency
to epimerize and hydrolyze under basic conditions, glycopeptides thioesters are difficult to
synthesize.27 Additionally, some glycopeptides thioesters are sensitive to repeated exposure to
TFA (SPPS by Boc strategy), or to acid-catalyzed hydrolysis which can occur in the
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glycopeptides thioester synthesis by the peptide hydrazide method.27c By using our method, we
can safely synthesize these glycopeptide thioesters, avoiding the harsh conditions required in
current methods.

1.2 Glycosylation and MUC1
We have already discussed how important peptides are for biological activities such as
cell signaling and neurotransmission. Of equal importance in biological systems are glycan
moieties and glycosylations on peptides and proteins28. These glycans play a huge role in peptide
and protein folding29, which in turn affects protein function and signaling30. Glycan structures
also play a role in immune surveillance, hormone action, and inflammatory reactions28, 31. Due to
the importance of correct glycans in proteins, errors in protein glycosylation can result in a
variety of diseases, including autoimmune diseases32, neurodegenerative diseases33, and cancer34.
There are two main types of naturally occurring glycans found in mammalian cells,
proteins, and peptides: N-glycans and O-glycans. N-glycans are found at the amide side chain of
asparagine, while O-glycans are found at the side chain of serine, threonine, hydroxylysine, or
tyrosine35. Glycans can also be found as a bridge in glycosylphosphatidylinositol, linking to
lipids36. Whether N-linked or O-linked, both glycosans play a role in the maintenance of protein
conformation and activity, as well as protein protection from proteolytic degradation and protein
intracellular trafficking and secretion28. N-glycosides, normally found as β-linkages37, also play a
role in folding, processing, and secretion of proteins from the ER and Golgi apparatus28. As such,
N-glycans occur solely on proteins released via the secretory pathway38. Approximately half of
all human proteins have been estimated to be glycosylated, and most of these glycosylations are
N-glycans39. O-glycosylations tend to be found as a GalNAc moiety bound through an α-linkage
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or a GlcNAc moiety bound as a β-linkage to the hydroxyl group of mostly serine or threonine40,
although the latter is rare. These glycan moieties can be either monosaccharides or
oligosaccharides containing a wide array of sugars41. While these linear or branched saccharide
moieties can contain great variety, the core of over 10% of human glycoproteins contain an α-OGalNAc at the reducing end. From this glycosylation span eight types of core O-GalNAc
structures which can be further elongated40. The most abundant type of O-GalNAc glycosylated
proteins belong to the Mucin family of glycoproteins. Mucins are heavily glycosylated mucus
proteins secreted mostly from the epithelium of gastrointestinal and respiratory tracts41. These
mucins have been attributed as playing a role in the genesis and/or development of a number of
congenital, developmental, and immune diseases42, and will be discussed further in this thesis.
While glycan moieties can range drastically from one glycan to another, they are all
assembled from the same ten monosaccharide units: fucose (Fuc), galactose (Gal), glucose (Glc),
N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc), glucuronic acid (GlcA),
iduronic acid (IdoA), mannose (Man), sialic acid (SA), and xylose (Xyl)43 (Figure 2). These ten
monosaccharide units assemble to create the more than 7,000 glycan structures which are
estimated to line the approximately 700 glycoproteins which generate the full diversity of
mammalian glycoproteins44.
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Fucose
Fuc

N-Acetylglucosamine
GlcNAc

Galactose
Gal

Glucose
Glc

Glucuronic Acid
GlcA

Iduronic Acid
IdoA

N-Acetylgalactosamine
GalNAc

Mannose
Man

Xylose
N-acetylneuraminic acid
Xyl
Neu5Ac
Figure 2: Ten monosaccharide units responsible for assembling the full diversity of
mammalian glycans (> 7000 structures)

Despite the challenge imbued by the high complexity and variability of these glycans,
research towards the identification and understanding of these glycan motifs is high. As such, it
is of high importance to gain access to well defined and controlled glycoproteins to further their
study and increase our understanding of their biological roles45. Although there have been great
strides made in the field of glycomics46, there is still much more to uncover, and improving
current synthetic and analytical methods is of paramount importance to the advancement of this
field47.
As mentioned previously, a large portion of O-glycosylated peptides belongs to the
Mucin family, which has been divided into two groups: secreted Mucins and membrane
anchored Mucins (MAMs). Both types of Mucins contain a tandem repeat sequence with a high
10

density of prolines, serines and threonines48. They are also heavily O-glycosylated, containing Olinkages at serine and threonine residues. This heavy glycosylation provides a protective barrier
against pathogen adherence and internalization49 and, in the case of MAMs, helps protect the
epithelial cell surface of respiratory and gastrointestinal tracts, as well as the ductal surfaces of
the liver, breast, pancreas, and kidney. The extended glycosylation also forms a mucinous gel
which helps lubricate and protect the epithelial cells from desiccation, pH changes, pollutants,
and microbes48. In addition to their protective function, several MAMs have been reported as
having signaling functions, either through cytoplasmic tails or through EGF-like domains50. Of
the 11 MAMs discovered to date, the most studied have been MUCs 1, 4, and16; this comes as
no surprise, as each of them has been found to be a tumor cell marker with high upregulation in
pancreatic, ovarian, and breast cancers, respectively48.
In healthy cells, MUC1 has the same characteristics that one would expect from a MAM:
a repeating tandem sequence, heavy O-GalNAc glycosylations on serine and threonine with
extended branching, and the protective properties that one would expect from a membrane
anchored Mucin. What makes MUC1 interesting is that its properties change drastically in
human epithelial cancers (Figure 3). In fact, these changes are distinct enough to warrant
aberrant MUC1 as an oncogenic molecule51. While there doesn’t seem to be an effect on the
amino acid sequence, the innate glycosylation of MUC1 is heavily affected in tumor associated
MUC1 (TA-MUC1). In breast cancer cells, loss of β6-GlcNAc-transferase activity results in the
absence of Core 2 O-glycans52; as such, breast cancer cells exhibit mostly Core 1 O-glycans
which would normally be only the beginning of the heavily branched glycosylation found in
healthy MUC1 glycoproteins53. There is also an overexpression of α2,3- and α2,6 sialyltransferases resulting in increased and premature sialylation, causing premature termination of
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chain elongation which results in truncated sugar branches. These truncated sugar branches are
abnormal, and as such result in antigens such as the Tn (GalNAc), and STn
(NeuNAc(2,6)GalNAc) antigens. Hypoglycosylation in MUC1 results in the loss of cell
polarity, which cascades into a number of harmful effects beyond the loss of endothelial cell
protection. Tumor invasion, proliferation, metastasis, apoptosis, drug resistance, inflammation,
and immune regulation have all been linked to the transcriptional regulation of MUC1 on their
corresponding genes48, 54.
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1.3 Biotinylation
The uncharacteristically strong interaction between biotin and avidin/streptavidin55
(collectively called (strept)avidin) has been known and utilized for decades56. Not only is this
non-covalent interaction incredibly strong (Kd ~ 10-14 to 10-16M), it is also highly stable against
extremes in pH, denaturants, heat, and proteolytic enzymes55. These properties have resulted in a
collection of methods currently known as (strept)avidin-biotin technologies55 and include
applications in labeling, separation and targeting, constructing self-assembling nanostructures,
and even pesticides57. The (strept)avidin-biotin complex has also had a profound effect on
molecular recognition (or biorecognition) strategies58. Antigen-antibody interactions have been
studied through (strept)avidin-biotin complexes as a model system for studies in biorecognition
phenomena, such as protein-protein, protein-peptide, protein-ligand and protein-DNA
interactions59.
Biotin “linkers” normally consist of three segments60 (Figure 4). The first segment is the
biotin moiety itself. While the valeric acid side chain is important for its interaction with
(strept)avidin, the carboxylic acid can be further derivatized without greatly affecting
(strept)avidin affinity. The second segment is the spacer, or a molecule which adds extra length
to the biotin linker so that immobilization in (strept)avidin will not be affected by steric factors.
This spacer is of key importance to the biotin linker, as it can help with water solubility
depending on its chemical nature. The spacer can also add additional features to the biotin linker,
such as a chemical or physical method of cleavage, facilitating protein/peptide/molecule release
after capture. The third segment consists of the reactive moiety responsible for forming the
covalent bond between the biotin linker and the protein/peptide/molecule in question. The most
common method of conjugating biotin is via its carboxylic acid on which is typically activated as
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its N-hydroxysuccinimide (NHS) ester. This activated ester can then undergo nucleophilic acyl
substitution, typically by the primary amines of lysine or the N-terminus of a protein/peptide,
creating a stable amide bond. An alternative method involves having an amine in place of an
activated ester on the biotin linker which can perform nucleophilic acyl substitution on activated
esters that a protein or peptide may have been derivatized with, once again forming a stable
amide bond. These are but a few of the methods available for biotinylation of a target molecule,
as currently over 40 different synthetic pathways for biotinylation have been proposed61.

Biotin

Handle

Spacer
Figure 4: Example of a commonly used biotin linker.

One last thing to note, adding to what has been stated above, is the importance of
choosing the right spacer for the biotin linker. To date the most popular biotinylation reagent
currently available on the market is Sulfo-NHS-LC (long chain)-biotin and similar derivatives.
These molecules are soluble in water; however, the aminocaproic acid chains found on them are
highly hydrophobic, causing these molecules to seek hydrophobic regions in the protein and
“hide” in them, making the biotin partially unavailable for binding to (strept)avidin. Moreover,
these hydrophobic LC-biotin labels may cause agglutination of the proteins/peptides. A popular
alternative to these aminocaproic acid spacers are polyethyleneglycol (PEG) spacers. These PEG
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spacers are much more water soluble and hydrophilic than their counterparts, while also retaining
solubility in organic solvents such as DMF and methylene chloride. They also show much less
agglutination than their counterparts62 and, as an added icing on the cake, PEG spacers have also
been shown to be less immunogenic than aliphatic chain-based spacers for in vivo applications63,
making them perfect candidates for immunological studies.

1.4 Native Chemical Ligation
Solid phase peptide synthesis, while an excellent method for synthesizing peptides, has
size limitations. In general, peptides longer than 50 amino acids in length may be difficult to
synthesize by SPPS alone27b, 64. To solve this problem, several ligation methods have been
developed over the course of the last twenty years. These ligation methods included hydrazone
ligation65, oxime ligation66, and thiazolidine ligation67; however, none of these ligation methods
are able to provide a native amide bond between the two peptide fragments. The one ligation
method which stands above the rest was innovated by Kent’s group in 1994 and was aptly named
native chemical ligation (NCL)27a.
Besides the formation of a native amide bond, NCL has several advantages over the other
ligation methods mentioned. There is minimal racemization68, it is regioselective69 and allows for
the use of unprotected peptide segments, and the reaction itself is performed at near-neutral pH at
high concentrations without aggregation of the reactants70. The reaction undergoes three major
steps (Scheme 2): First, there is (usually) a thiol-thioester exchange between the (typical) alkyl
thioester and an externally added alkyl or aryl thiol, creating a kinetically more reactive
thioester70. Following this thiol-thioester exchange, there is a transthioesterification reaction
between the C-terminal thioester of peptide 1 (now a more reactive thioester) and the N-terminal
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cysteine of peptide 2. This forms a covalent bond between the two peptide fragments, bringing
them in close proximity to each other. This close proximity is essential for step three, which
involves an S to N acyl transfer rearrangement resulting in native amide bond formation. While
steps one and two are reversible, step three locks the newly formed peptide in place71.

Step 1:
Thiol-thioester exchange

Step 2:
Transthioesterification

Step 3:
S to N acyl shift

Scheme 2: General steps of NCL

As can be gathered from these three steps, there are certain requirements that must be met
for a peptide sequence to be eligible for NCL. The two main requirements that must be met are
the presence of a C-terminal thioester and the presence of an N-terminal cysteine. However,
since the development of this technique, huge strides have been made towards its improvement,
to the point where an N-terminal cysteine is no longer an absolute necessity. For example, in
auxiliary mediated ligation (AML) the thiol required for transthioesterification is actually
attached to the N-terminal amine, not the side chain. After transthioesterification and S to N acyl
shift, the thiol moiety (commonly Nα-(1-phenyl-2-mercaptoethyl) or 4,5-dimethoxy-216

mercaptobenzylamine) can be chemically removed, yielding the desired peptide sequence
without the need of an N-terminal cysteine72. Desulfurization has also been employed after NCL
to convert any unprotected cysteines to alanines, essentially allowing the use of alanine in a
peptide sequence as a temporary cysteine for NCL73. A similar approach was applied to
phenylalanine, where the β-carbon contains a mercaptan group which is removed by
desulfurization after completion of the NCL74. Valine has also been modified as a possible Nterminal cysteine alternative. β,β-dimethylcysteine is used for NCL, which after radical mediated
desulfurization transforms into valine, adding yet another N-terminal amino acid with NCL
capabilities73.
The C-terminal side of NCL has seen some interesting developments as well. It has been
discovered by Kent’s group that different thioesters have very different reaction kinetics in
NCL70. It was discovered that aryl thioesters react much faster than alkyl thioesters; this
discovery led to the development of kinetically controlled NCL. In this method, two thioesters,
an alkyl and an aryl thioester, can both be present during NCL. By taking advantage of the
substantially higher reactivity of aryl thioesters over alkyl thioesters, we can control the products
of this convergent ligation, yielding a single product from three converging pieces. However,
aryl thioesters are highly labile under basic conditions, meaning that an aryl thioester cannot be
used in the Fmoc strategy of SPPS.

1.5 Photoacylation of nucleophiles with N-acyl-7-nitroindolines
Photoreactive molecules are not new to the world of chemistry. From organic to
inorganic and organometallic chemistry, photochemistry has found a place in almost every niche
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of the field. This is not surprising, as photoreactions tend to be orthogonal to other common
reaction conditions.
Of special interest to our research group are nitroindoline derivatives which become
photoreactive upon nitrogen acylation. It was Patchornik who first discovered the photoreactive
properties of N-acyl-7-nitroindoline in the late 1970’s75. Upon irradiation with light near 350 nm
(UV light), N-acyl-7-nitroindolines undergo an N to O acyl shift, forming a highly electrophilic
nitronic anhydride intermediate76. Due to this highly reactive intermediate, n-acyl nitroindoline
derivatives make for great acylating agents. Nucleophiles present can attack the nitronic
anhydride, transferring the acyl group from the nitroindoline derivative to the nucleophile
(Scheme 3). This reaction yields nitroindoline as a byproduct, which can be recovered, reacylated, and utilized as an acylating agent once more.

Nitronic anhydride
Scheme 3: Nitronic anhydride formation upon irradiation with 350 nm
light, followed by trans-acylation using a nucleophile.
This nitronic anhydride species was at first thought to occur through a tetrahedral
intermediate which undergoes decay to form the nitronic anhydride76. However, semi-empirical
potential energy surface calculations suggest that this nitronic anhydride intermediate is actually
formed through a sigmatropic rearrangement77. In addition, there are two major reactive
pathways that these nitronic anhydride species can undertake115 (Scheme 4). In the presence of a
nucleophile, the nitronic anhydride acts as an acylating agent, acylating the nucleophile and
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forming nitroindoline as a byproduct. In the presence of protic solvents of sufficient acidity,
however, a different pathway takes place. This “pathway B” results in the formation of a
carboxylic acid (from the acyl group) and nitrosoindole (from the nitroindoline). Mixed
pathways have also been observed.78

Scheme 4: Divergent pathways of nitronic anhydride intermediate
depending upon the presence of protic solvents.

This theory was further proven by our lab by incorporating heavy water (H218O) into a
photoreaction. It had been observed that when trying to make an ethyl thioester through
irradiation of n-acyl-7-nitroindoline with ethyl mercaptan as a solvent (pKa = 10), only the
carboxylic acid was formed. At first this was attributed to hydrolysis, as any small amount of
water present could potentially become acylated, yielding a carboxylic acid. This theory was
tested by using 3% heavy water along with ethyl mercaptan as solvent during the photoreaction.
If the nitronic anhydride intermediate was indeed undergoing hydrolysis, the carboxylic acid
produced would contain 18O instead of 16O and would thus be observable through MS. However,
the photoreaction yielded free acid with mostly 16O, meaning that hydrolysis was not
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significantly responsible for carboxylic acid formation. To ensure that there was no oxygen
exchange after the reaction, another test was performed where an Obt ester intermediate was
formed, and heavy water was introduced into the reaction. In this case the carboxylic acid
formed after nucleophilic acyl substitution did indeed contain predominantly 18O. These tests
corroborate the existence of pathways A and B (Scheme 4). Newly acquired data seems to
indicate that pathway B takes place due to acidic protic solvents with pKa between 10 and 16
(Alfredo Ornelas, unpublished preliminary data). All of these results have elicited a need for
creating a new method of synthesizing esters and thioesters in particular. This led the team to
conduct the photoacylation in a one-pot-two-reactions procedure.
In the one-pot-two-reactions procedure, an activated ester is formed first under aprotic,
anhydrous conditions during irradiation of the acylated nitroindoline (Scheme 5). After the
irradiation is complete and the activated ester is formed, the desired nucleophile is added to the
reaction mixture “in the dark,” meaning that UV light exposure is no longer necessary. This onepot-two-reactions method has been successfully applied in our lab for the synthesis of numerous
oxo- and thioesters.78-79

Scheme 5: Example of one-pot-two reaction procedure for the
formation of phenylthioesters.

Due to their great acylating potential, N-acyl-7-nitroindolines have been used as
protecting groups for carboxylic acids.75, 80 5,7-dinitroindoline and 5-bromo-7-nitroindoline (Bni)
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were introduced in 1975 by Amit et al. as protecting groups for carboxylic acids, demonstrating
that in the presence of ~1% water in an aprotic organic solvent, free carboxylic acids and
nitroindoline could be formed in near quantitative yields75. Patchornik et al. demonstrated the
validity of nitroindoline derivatives by using Bni at the C-terminus of a peptide and utilizing it
for a segment condensation reaction81. Not only did he demonstrate that it worked, the products
of these photoreactions yielded peptides with minimal epimerization, a feat which is of great
importance to peptide chemists. Large amounts of epimerization will lead to D-amino acids
which are not present in naturally occurring peptides and proteins. This means that further
biological studies with these synthetic peptides can yield results which do not directly correlate
to their naturally occurring counterparts. The low epimerization levels and high acylation yields
achieved by N-acyl Bni and other nitroindoline derivatives marks it as a very promising
protecting group and activator for carboxylic acids in peptide chemistry.
Because of its great potential, our group wanted to incorporate these nitroindoline
derivatives into peptide synthesis, and we did it in the form of 5-carboxylic acid-7nitroindoline.78 The carboxylic acid present on the nitroindoline derivative can be used to anchor
an amino acid/peptide to a standard polystyrene resin for SPPS, while the nitroindoline itself can
form an amide bond with the C-terminus of an amino acid. After anchoring the first
photoreactive amino acid, standard Fmoc SPPS can take place. Once peptide synthesis is
complete, the versatility of this nitroindoline derivative really kicks in. The photoreactive peptide
can be cleaved using standard methods, yielding a fully protected peptide with an orthogonal
photoreactive protecting group on its C-terminus. This fully protected photoreactive peptide can
be further derivatized, affording modifications such as the free acid, biotinylation, and thioester
moieties. Also, due to its potential for activation using UV light, the photoreactive peptide can be
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activated while still on the beads. With the right conditions and nucleophile present (i.e. an
amine nucleophile), simultaneous C-terminal modification and release from the beads can be
achieved. If a carboxylic acid is desired, direct photorelease from the beads can be done by
simply irradiating the beads under protic conditions, yielding a fully protected peptide with a free
carboxylic acid on the C-terminus. All of these routes and modifications can be seen in Scheme
6.

Scheme 6: Versatility of nitroindoline linker in SPPS.
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1.6 Hypothesis
Due to past success in our laboratory in the synthesis of photoreactive peptides using
Fmoc/tBu chemistry in SPPS, and the subsequent success in the photochemical formation of
oxo- and thioesters under near-neutral conditions using 350 nm light, we believe that we can
expand the scope of these photoreactions to include glycopeptides for the formation of thioesters,
amides, and free acid derivatives. Moreover, we believe that the free acid and biotinylated
derivatives can be achieved via a direct photorelease method, where the solid support containing
our photoreactive (glyco)peptides is exposed to the desired nucleophile and 350 nm light,
effectively resulting in trans-acylation of the desired nucleophile with simultaneous release from
the resin.
1.7 Specific Aims
Specific Aim 1


Synthesize target (glyco)peptides by Fmoc strategy SPPS:
1a)

Synthesis of Fmoc-Gly-Ind(OH) (1)

1b)

Synthesis of Tn (2) and STn (3) glycoamino acids

1c)

Synthesis of biotin linker (4)

1d)

Synthesis of Boc-Arg(Pbf)-Pro-Ala-Pro-Gly-Ser(tBu)-Thr(tBu)-Ala-Pro-Pro-AlaHis(Trt)-Gly-Ind-Sieber (5)

1e)

Synthesis of Boc-Arg(Pbf)-Pro-Ala-Pro-Gly-Ser(tBu)-Thr(Tn)-Ala-Pro-Pro-AlaHis(Trt)-Gly-Ind-Sieber (6)

1f)

Synthesis of Boc-Arg(Pbf)-Pro-Ala-Pro-Gly-Ser(tBu)-Thr(STn)-Ala-Pro-ProAla-His(Trt)-Gly-Ind-Sieber (7)

1g)

Synthesis of cleaved (glyco)peptides 8-10 for homogeneous reactions.
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Specific Aim 2
2a)

Homogeneous photoreactions in solution:

2b)



Synthesis of (glyco)peptide acids 11-13



Synthesis of biotinylated (glyco)peptides 14-16



Synthesis of (glyco)peptide thioesters 17-19

Heterogeneous/direct photorelease reactions:

2c)



Synthesis of (glyco)peptide acids 11-13



Synthesis of biotinylated (glyco)peptides 14-16



Synthesis of (glyco)peptide thioesters 17-19

Peptide deprotection and characterization.


Side chain deprotection of free acid, biotinylated, and thioester (glyco)peptides 20-28



Synthesis of fully deprotected glycopeptides 29-32
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Chapter 2: Results and Discussion

2.1 Specific Aim 1
2.1.1 Synthesis of Fmoc-Gly-Ind(OH)

33

35

34

36

37

38
39

Hogenauer. T.; et al. Org. Biomol. Chem. 2007, 5, 759
Ornelas, A. et al. unpublished data

Scheme 7: Synthesis of Fmoc-Gly-Ind(OH).

1

The first step towards the synthesis of the photoreactive amino acid is the synthesis of 5carboxylic acid-7-nitroindoline which will act as the anchor for the growing peptide to the solid
support. Our lab has developed an efficient 7 step method for its synthesis starting with 5carboxylic acid indole78, 82 (33) (Scheme 7). With 5-allyl ester 38 in hand, the coupling to FmocGly-OH by using thionyl chloride was tried first, which is standard procedure. However, this
reaction was long (28 h) and the yield was subpar (55%). Future reactions were done using the
Appel reaction with shorter reaction times (under 21 hours) and the yield is slightly increased
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(67% yield over 2 steps) However, the triphenylphosphine oxide byproduct of the Appel reaction
has the same Rf as Fmoc-Gly-Ind(OAll) (39), making it near impossible to separate by silica
chromatography. Therefore, the next reaction step was performed without separating
triphenylphosphine oxide from 36 and the yield was calculated over 2 steps after allyl
deprotection, where Fmoc-Gly-Ind(OH) (1) has a different Rf than triphenylphosphine oxide. It
should be noted that the triphenylphosphine oxide seems to have no effect on the deallylation
reaction, as TLC shows near complete conversion of the allyl ester 39 to the free carboxylic acid
1.

2.1.2 Synthesis of Tn and STn glycoamino acids

40

41

Araki, K.; et al. Carbohydrate Research. 1982, 109, 143-160

42
Birnbach, S.; et al. Carbohydrate Research. 1990, 202, 207-223

43

2
Kuduk, S.; et al. Journal of American Chemical Society. 1998, 120, 12474

Heiner, S.; et al. Bioorg. Med. Chem. 2006, 14, 6149-6164

Scheme 8: Synthesis of Fmoc-Thr(-GalNAc)-OtBu glycosyl acceptor.
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45

44

46

47

Scheme 9: Synthesis of sialic acid glycosyl donor.

47
48

49

3

Heiner, S.; et al. Bioorg. Med. Chem. 2006, 14, 6149-6164

Scheme 10: Synthesis of Fmoc-Thr(STn)-OH.
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The Tn83 and STn84 antigens were synthesized following known procedures (Schemes 810). There was only one major change to these methods. Halogenation of the sialic acid 45 is
normally carried out with HCl in AcCl. However, when following this method, the subsequent
reaction (xanthate activation) never worked as desired. Several methods were tried when making
the HCl solution in AcCl, mainly by using an HCl tank and by forming HCl as the result of
reacting NaCl and H2SO4 and then bubbling the HCl gas into AcCl. What did work for me was
using AcCl neat and waiting for it to hydrolyze and form HCl gas naturally. This reaction took
quite a long time (3 days), but the subsequent xanthate activation worked rather well (70% yield
over 2 steps), indicating the formation of the halogenose 46 on the previous step.
2.1.3 Synthesis of biotin linker

50

51

52

53

54

4
Scheme 11: Synthesis of Biotin-ethylene glycol-NH2 biotin linker.
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The biotin linker 4 was also synthesized following known methods85 (Scheme 11).
However, purification of this compound containing a free primary amine proved quite
challenging. To solve this, a different synthetic route was approached. The diamine 52 was first
singly protected using trityl chloride, yielding 53. This compound is then easily purified by doing
an aqueous workup as the starting material is highly water soluble, while the singly protected
product is water insoluble. This can then react with the activated biotin pentafluorophenyl ester
(51). For the removal of the trityl group, a standard TFA and TIS solution was used. After
complete trityl removal was observed in TLC, the solution was neutralized with NaOMe and
amberlyst was added to the reaction mixture. The primary amine forms a salt with the sulfonic
acid on solid support; once TLC no longer showed the biotin linker present (indicating its
attachment to the amberlyst from salt formation), the solution was be filtered and the resin
washed, removing all byproducts formed from the trityl deprotection. The biotin linker can then
be released from the solid support by exposure to ammonium hydroxide, filtered, and
lyophilized, yielding pure product 4.
2.1.4 Synthesis of (glyco)peptides 5-7

Figure 5: Thirteen amino acid sequence taken from MUC1 tandem repeat region. Three
variants of the peptide (Pepties 5-7) containing tBu, Tn antigen, or STn antigen at Threonine.
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The three (glyco)peptides to be synthesized can be seen in Figure 5. Peptide 1 was
synthesized following standard Fmoc/tBu SPPS chemistry. The only difference was the coupling
of the first amino acid, as it contains the photoreactive moiety Fmoc-Gly-Ind(OH) (1). This was
coupled using only 1.5 equiv. of the photoreactive amino acid for one hour; the low number of
equivalents were used because full coupling of this first amino acid was not desired. This was done
to minimize aggregation of the peptide as it gets longer. Coupling of the first photoreactive amino
acid using these conditions yielded ~50% coupling to the resin. The detailed reaction conditions
for this peptide and the following two glycopeptides can be found in the experimental section
under Solid Phase Peptide Synthesis (pg. 51).
Glycopeptides 2 and 3 were synthesized following the same procedure as with peptide 1,
with one exception: the coupling of threonine containing the sugar moieties was coupled using less
equivalents than Fmoc-Thr(tBu)-OH. Fmoc-Thr(Tn)-OH was coupled using 2 equiv. of the
glycosylamino acid, HATu (2.4 Eq), HOAt (2.4 Eq), and NMM (5 Eq) in 2.7 mL NMP for 8 hours.
Fmoc-Thr(STn)-OH was coupled using 3 (1.74 Eq), HATu (2.5 Eq), HOAt (2.5 Eq), and NMM
(5 Eq) in 0.5 mL NMP for 30 minutes at 50oC. Both of these methods worked well, as the coupling
yields were 94% and 84%, respectively.

2.1.5 Synthesis of cleaved (glyco)peptides 8-10

Scheme 12: Synthesis of cleaved (glyco)peptides 8-10
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Once SPPS was finished, the resin containing the peptides was washed with NMP and
DCM, co-evaporated with dry Benzene to remove any traces of water, and subsequently used for
the photorelease reactions. For homogeneous reactions, the peptide first had to be cleaved from
the Sieber amide resin. This was done with 1% TFA in DCM. The full procedure can be found in
the experimental section (pg 52). Purification of the peptides was done first by precipitation with
cold diethyl ether, then by silica chromatography (D:M 9:1 to 6:1). The purity of the peptides was
then observed in FPLC and their masses were measured using a high resolution ESI-MS.

2.2 Specific Aim 2
2.2.1 Homogeneous Reactions in Solution
2.2.1.1 Synthesis of (glyco)peptide acids 11-13

11)
12)
13)

Scheme 13: Synthesis of free acid (glyco)peptides via homogeneous reaction conditions.
The photoreactive (glyco)peptides were dissolved in THF/Water (9:1) (molarity = 0.01)
and irradiated under 350 nm light for 4 hours (Scheme 13). The reactions were then concentrated
and the (glyco)peptide acids were purified by silica chromatography.
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2.2.1.2 Synthesis of biotinylated (glyco)peptides 14-16

Scheme 14: Synthesis of biotinylated (glyco)peptides under homogeneous reaction conditions.
The photoreactive (glyco)peptides and the biotin linker were co-evaporated with dry
benzene to remove any water present, followed by lyophilization with dry Benzene. They were
both left in a desiccator containing phosphorus pentoxide overnight before use, along with Nhydroxysuccinimide. The photoreactive (glyco)peptide (1 equiv.), biotin linker (1.2 equiv.) and
HOSu (3 equiv.) were transferred to a dried, argon flushed test tube and dissolved in dry
THF:DMSO (8.5:1.5). Freshly activated, ground up 4Ao molecular sieves were added and the
reactants were allowed to stir for 10 minutes. The test tube was then placed in a cooling chamber
inside the photoreactor and irradiated with 350 nm light for 4 hours (Scheme 14). The reaction was
then filtered, dried, and purified by silica chromatography. For more information regarding
reaction conditions, see experimental section (pg. 54).
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2.2.1.3 Synthesis of (glyco)peptide thioesters 17-19

Scheme 15: Synthesis of thioester (glyco)peptides via homogeneous reaction conditions.

The photoreactive (glyco)peptide and HOSu were dried as previously described. The
photoreactive (glyco)peptide (1 equiv.) and HOSu (2 equiv.) were transferred to a dried, argon
flushed test tube and dissolved in dry DMF (molarity = 0.05). Freshly activated, ground up 4Ao
molecular sieves were added and the reaction was allowed to stir for 10 min. The test tube was
then placed in a cooling chamber inside a photoreactor and photoirradiated for 2 hours (Scheme
15). The reaction was then taken out of the photoreactor and 10 equiv. of thiophenol were added.
After 2 hours the reaction was transferred to a 10 mL centrifuge tube and precipitated using cold
diethyl ether, then purified by reverse phase FPLC. Yields for thioester derivatives were calculated
after side chain deprotection (section 2.2.3.1, pg. 37).
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2.2.2 Photorelease Photoreactions
2.2.2.1 Synthesis of (glyco)peptide acids 11-13

Scheme 16: Synthesis of (glyco)peptide acids via photorelease reaction conditions.
All 3 peptides were photoreleased following the same reaction procedure, which can be
found in the experimental section (pg. 52). To ensure the complete photorelease is accomplished,
10% of water was added to the solvent (THF) and the reaction was left in the photoreactor (350
nm light) for 15 hours (Scheme 16). The peptide was then be filtered, concentrated, and purified
by silica chromatography.
2.2.2.2 Synthesis of biotinylated (glyco)peptides 14-16

Scheme 17: Synthesis of biotinylated (glyco)peptides via photorelease reaction conditions.
34

All 3 (glyco)peptides were biotinylated and photoreleased following the same reaction
procedure, which can be found in the experimental section (pg. 53). The resin containing the
(glyco)peptides were first prepared by washing with NMP and DCM to ensure no other reactants
are left in the resin, followed by co-evaporation using dry benzene to remove as much water as
possible. The resin was then left in the desiccator overnight and used the following day. The
amount of peptide attached was determined based on the weight of the resin.
The auxiliary nucleophile (N-hydroxysuccinimide) was kept in a desiccator under argon.
The biotin linker was dried via co-evaporation with dry benzene and finally lyophilized with dry
benzene and left in the desiccator overnight before use. N-hydroxysuccinimide (3 equiv.) and the
biotin linker (1.2 equiv.) were dissolved in THF/DMSO (85%, 15%) and transferred to a dried,
argon flushed test tube containing the dried resin with the (glyco)peptide. Ground up 4Ao
molecular sieves were added and the reactants were allowed to stir for 10 minutes. At this point
the test tube was transferred to the photoreactor, placed in a cooling chamber, and reacted under
350 nm light for 15 hours (Scheme 17). It should be noted that the auxiliary nucleophile was
present not only to act as an intermediate nucleophile in the reaction, but also to minimize the
basicity of the reaction to prevent -elimination of the sugar moieties. Once done, the reaction was
filtered through a cotton plug, concentrated, and purified via silica chromatography.

2.2.2.3 Synthesis of (glyco)peptide thioesters 17-19

Scheme 18: Proposed future synthesis of (glyco)peptide thioesters via photorelease reaction conditions
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For the formation of (glyco)peptide thioesters via a heterogeneous photoreaction pathway,
we first had to form an activated ONSu ester. Due to the success of biotinylation reactions in these
heterogeneous conditions, we first decided to try to generate the activated ester using 3 equiv. of
HOSu under the same reaction conditions as in section 2.2.2.2 (pg. 35). However, the only
observable peptide formed after photoirradiation contained a carboxylic acid; no ONSu ester was
observed. The reaction was repeated again, this time using 5 equiv. of HOSu, with the same results.
At this time we decided to continue test photorelease reactions on a smaller dipeptide
(Fmoc-Phe-Gly-Ind-Rink) so as not to expend our MUC1 peptide. Several reaction conditions
were tested, such as varying equivalents of HOSu (2.5 equiv. to 25 equiv), solvent quantities (0.2
mL to 0.9 mL THF), reaction times (6 h to 17 h), and molecular sieve composition (full versus
ground up). Some of these reaction conditions yielded the desired ONSu ester; however, the ratio
of ONSu ester to carboxylic acid formation was usually 1:1 or worse. We also encountered a
problem with conversion of the ONSu ester to the desired thioester. We tried using different
amounts of thiophenol (10 equiv. to 50 equiv.) and varying reaction times (3 h to 3 days) but never
achieved full conversion. Due to these complications we decided to continue the research project
without the inclusion of thioester formation from heterogeneous photorelease conditions.
There are several theories as to why the photorelease of the activated ONSu ester didn’t
work as desired. One theory is that perhaps we needed even more equivalents of HOSu in the
reaction so as to facilitate attack of the nitronic anhydride upon UV light irradiation. Another
theory involves using less HOSu ester instead of more. As mentioned previously, in the presence
of protic solvents, the undesired pathway B takes place, generating a carboxylic acid in place of
the desired acylated nucleophile. HOSu, while not a solvent, is protic and can provide the required
hydrogen for pathway B to take place. Less equivalents of HOSu in combination with a solvent
which cannot carry a proton (i.e. not THF) might provide an answer to this problem. As for the
problem concerning thioester formation from the ONSu ester, there are also a number of theories.
If the reaction was too dilute, it would be harder for thiophenol to attack the activated ester. It is

36

also possible that the thiophenol oxidized to the disulfide, consuming the thiophenol. These
theories have yet to be explored.

2.2.3 (Glyco)peptide deprotection and characterization
2.2.3.1 Side chain deprotection of free acid and biotinylated (glyco)peptides 20-28

Scheme 19: Side chain deprotection
After the photoreactions, one free acid and biotinylated derivative for each peptide (i.e.
peptides 1, 2, and 3) were deprotected to obtain the FPLC profile for each deprotected peptide.
Deprotection was done using TFA:TIS:H2O 15:0.9:0.9 over two hours. The peptides were then
precipitated using diethyl ether and purified using FPLC (see experimental section). The yields
ranged from 97% to quantitative.

2.2.3.2 Synthesis of fully deprotected glycopeptides 29-32

Scheme 20: Tn deprotection
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For the deprotection of the sugars, glycopeptides containing the Tn antigen were dissolved
in methanol (5 mL) and a solution of NaOMe was added until the pH reached 10. This solution
was stirred at room temperature for 40 hours, at which point it was neutralized with acetic acid
and precipitated with cold diethyl ether. The glycopeptides were then purified by reverse phase
FPLC.

Scheme 21: STn deprotection
Glycopeptides containing the STn antigen were dissolved in MeOH with 1M NaOH (1%
v/v) and stirred at room temperature for 2.5 hours. The mixture was then neutralized with 90 mM
aq. AcOH to a pH of 6 and evaporated. The glycopeptides were then dissolved in 5mM aq. NaOH
and stirred at room temperature for 3 h 45 min. The solution was again neutralized to a pH of 6
with 90 mM aq. AcOH, then frozen and lyophilized. The glycopeptides were then purified by
reverse phase FPLC.
Due to the base sensitivity of thioesters, glycan moieties in glycopeptides 18 and 19 were
not deprotected. All (glyco)peptides were characterized using a high resolution ESI-MS. Singlyand doubly charged species containing H+, Na+, and K+ were normally found. FPLC and MS data
can be found under the supplementary material section (pg. 62).
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2.4 Results
Table 1: Reaction yields for homogeneous and photorelease photoreactions.
* = Yields calculated after photoreaction and side chain deprotection steps
Yields in red are after 26 steps found in SPPS, cleavage, and the photoreaction.
Yields in green are after 28 steps found in SPPS, cleavage, photoreaction, and deprotection.

Homogeneous
Starting

Free Acid

Biotin

Photorelease
Thioester

Free Acid

Biotin

Materials
Peptide 5

Peptide 6

Peptide 7

(11)

(11)

(14)

(14)

(17)

(17)

(11)

(14)

73%

31%

80%

34%

77%*

33%

87%

64%

(12)

(12)

(15)

(15)

(18)

(18)

(12)

(15)

90%

34%

78%

30%

84%*

32%

92%*

67%

(13)

(13)

(16)

(16)

(19)

(19)

(13)

(16)

92%

47%

79%

40%

79%*

40%

84%

76%

The photorelease yields shown in Table 1 (red) are representative of 26 synthetic step: 12
coupling steps, 12 Fmoc deprotection steps, cleavage and photoreaction; 27 synthetic steps in
green for the thioesters (including side chain deprotection). While we can cleave and purify the
photoreactive (glyco)peptides for our homogeneous photoreactions, the same cannot be done for
photorelease reactions, where the (glyco)peptide remains attached to the solid support. For this
reason, yields for photorelease reactions are a representation of both SPPS and the photoreaction
itself. To make a better comparison of the two methods, we have decided to recalculate the yields
for homogeneous reactions (Table 1 in red) taking into account (glyco)peptide cleavage yields
(Table 2).
Table 2: Cleavage yields for (glyco)peptides 8-10.
Peptide

Cleavage

Glycopeptide Glycopeptide

8

9

10

43%

38%

51%
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Chapter 3: Conclusions
By the end of this project, we were able to successfully complete most of the goals
specified in our specific aims. We were able to synthesize all the building blocks required for the
main project following known procedures. This includes the synthesis of Fmoc-Gly-Ind(OH) (1),
the biotin linker 4, and both Tn and STn containing Threonine glycosylamino acids 2 and 3.
With these building blocks now available, we were successful in synthesizing the MUC1 peptide
5, MUC1 Glycopeptide (Tn) 6, and MUC1 Glycopeptide (STn) 7.
With the 5 - 7 synthesized, we were able to perform the photoreactions specified under
specific aim 2, designed to showcase the versatility of this photoreactive N-acylnitroindoline
linker. The homogeneous photoreactions of (glyco)peptides 5-7 yielded good results for both
free acid formation (73%, 90%, and 92) and biotinylation (80%, 78%, and 79%). Thioester
formation at the C-terminus using the one-pot-two-reactions procedure also yielded good results
for the MUC1 peptide 5 (77%), MUC1 glycopeptide (Tn) 6 (84%), and MUC1 glycopeptide
(STn) 7 (79%). These yields can probably be improved by removing water from the reaction
mixture more thoroughly prior to irradiation. One way to accomplish this is to allow for longer
drying times with molecular sieves.
The photorelease reactions also yielded good results, especially if we take into account
that these reactions are over 26 synthetic steps. To do a more fair comparison between the
photoreleased reactions and the homogeneous reactions, we should look at the yields over the
same number of steps (Table 1). Free acid formation for the MUC1 peptide (87%), MUC1
glycopeptide (Tn) (92%), and MUC1 glycopeptide (STn) (84%) resulted in yields much higher
than their homogeneous counterparts over the same 26 synthetic steps (31%, 34%, and 47%
respectively). Biotinylation via photorelease conditions for MUC1 peptide (64%), MUC1
glycopeptide (Tn) (67%), and MUC1 glycopeptide (STn) (76%) had similar results, with their
counterparts having yields of 34%, 30%, and 40%, respectively. By comparing our photorelease
and homogeneous yields over the same number of synthetic steps, we can safely make the
40

following statement: our photorelease method is much more efficient at not only forming
carboxylic acid derivatives of our (glyco)peptides, but also at acylating primary amines directly
from the resin. Whether this is the result of avoiding acidic conditions which could form
byproduct formation, or from avoiding extra purification steps after cleavage, the fact is that
photorelease yields are much higher than homogeneous yields when a comparison over the same
number of synthetic steps is made.
However, we were unable to synthesize (glyco)peptide thioesters 17-19 using similar
photorelease conditions as our biotinylated derivatives. As explained before, this could be due to
a number of reasons, such as not enough (or too much) auxiliary nucleophile present during the
photoreaction, or the presence of too much water. Further experiments need to be performed
before a consensus on whether it is possible to generate activated esters via a photorelease
method is possible or not.
There are aspects to this photoreaction to be noted here. While our nitroindoline linker
for SPPS isn’t the first photoreactive linker to be used for SPPS, it is one of the more versatile
and condition-friendly photoreactive linkers available today. Most photoreactive linkers
currently in the market yield exclusively free carboxylic acids after photolysis. If a different
modification is desired, further synthetic steps are required. Our nitroindoline linker can take
advantage of various nucleophiles for trans-acylation, which can ultimately result in a wide
variety of C-terminal modifications, such as the thioesters and amides discussed in this thesis. In
addition, many other photoreactive handles for SPPS are not friendly towards the most
commonly used methods. These linkers either have a propensity for diketopiperazine formation,
or are simply incompatible with Fmoc/tBu chemistry. Our nitroindoline linker attaches to both
the peptide chain and the solid support via amide bonds, which are resistant to both
diketopiperazine formation and tolerate the conditions used in Fmoc/tBu SPPS chemistry.
In the end, what these results indicate is that this photoreactive nitroindoline linker can be
very useful in the field of SPPS. We can generate protected (glyco)peptides with a carboxylic
acid on the C-terminus under neutral conditions. This can be done under both homogeneous or
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heterogeneous (photorelease) conditions, resulting in a C-terminal free acid (glyco)peptide which
can be further modified. While not incredibly exciting, generating a free acid at the C-terminal of
protected (glyco)peptides is oftentimes necessary; for example, fragment peptide condensation
reactions for the assembly of larger peptide sequences from two smaller sequences require one of
the protected (glyco)peptides to contain a C-terminal free acid.
We have also seen that photochemical biotinylation of these MUC1 (glyco)peptides was
achieved in good yields, both homogeneously and heterogeneously, which is really quite
impressive. This means that there are two options available when the acylation of a (primary)
amine is necessary. One can either cleave the (glyco)peptide off the resin, purify, then perform
the reaction, or (my favorite) one can perform simultaneous biotinylation and photorelease as
soon as the peptide synthesis is finished (after washing and drying the resin). This biotinylation
under heterogeneous conditions saves the chemist a reaction and purification step: those of
cleavage using standard conditions and the purification of the (glyco)peptide. While biotinylated
(glyco)peptides are useful for various applications involving binding to (strept)avidin, we used
this particular biotin linker as a model for any primary amine. In principle, any primary amine
can be used during the photoreaction with similar results. Our results show that primary a
primary amine in the presence of N-hydroxysuccinimide does not cause -elimination of the Oglycan. There was a small concern that the acid-base interaction between N-hydroxysuccinimide
and the primary amine could potentially result in a non-nucleophilic ammonium salt; however,
the resulting yields were quite good, meaning that enough free amine is present in the reaction
mixture.
By using our photochemical one-pot-two-reactions procedure method we can effectively
synthesize glycopeptide thioesters in good yields (85% and 79% for Tn and STn-containing
glycopeptides, respectively). This method is incredibly mild, effective, and specific, making it a
great option for the formation of peptide and glycopeptides thioesters. Since we generate an ONSu
ester during the photoreaction in the one-pot-two-reactions method, we can in theory add any
nucleophile to the reaction post-activated ester formation. In other words, while we showcase the
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one-pot-two reactions procedure for the formation of thioesters, we can in theory use it for the
acylation of any nucleophile, given that its nucleophilicity is high enough to displace the auxiliary
nucleophile (ONSu ester, OBt ester, etc…). While the formation of the ONSu ester was
unsuccessful under the heterogeneous photoreaction conditions we tried, we believe that with
further exploration we can find the right conditions to achieve this.
In closing, we have been successful in demonstrating the versatility of our Nacylnitroindoline linker for SPPS by forming C-terminus thioester derivatives in a one-pot-tworeactions method in good yields. This was showcased by our synthesis of MUC1 peptide and
glycopeptide thioesters with the Tn and STn antigens, the latter of which contains a notoriously
acid sensitive Neu5Ac group. On top of that, we were successful in synthesizing C-terminal free
acid and biotinylated derivatives in not only homogeneous reaction conditions, but in
heterogeneous photorelease conditions as well, both in good yields.
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Chapter 4: Experimental
Synthesis of Fmoc-Gly-Ind(OH) (1)
In a dried and argon flushed round bottom, Fmoc-Gly-Ind(OAll) (36, crude, ~1.01 mmol)
was dissolved in dry THF (12 mL). N-methylaniline (1.09 mL, 10.1 mmol) and
tetrakis(triphenylphosphine)palladium(0) (0.117 g, 0.101 mmol) were added and the reaction
was allowed to stir for 30 min at room temperature. The THF was then evaporated and the crude
mixture purified by column chromatography (DCM:MeOH 14:1). 0.418 g (85% yield) of FmocGly-Ind(OH) (1) were recovered. Rf 0.15 (DCM:MeOH 14:1). 1H NMR (600 MHz, 23.4 °C,
DMSO-D6, δH) 8.11 (s, 1H, Ind-ArH), 8.09 (s, 1H, Ind-ArH), 7.90 (d, 2H, Fmoc-ArH), 7.74 (d, 2H,
Fmoc-ArH), 7.42 (dd, 2H, Fmoc-ArH), 7.33 (dd, 2H, Fmoc-ArH), 4.29 (m, 4H, NCH2, α-CH2), 4.25
(t, 1H, Fmoc-CH), 4.20 (d, 2H, Fmoc-CH2), 3.28 (t, 2H, NCH2CH2); MS: m/z [M+Na]+cal = 510.1,
[M+Na]+obs = 509.9.
Synthesis of N-(9-Fluorenylmethoxycarbonyl)-O-(3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-D-galactopyranosyl)-L-threonine tertbutyl ester (2)
39 (0.219 g, 0.308 mmol) was dissolved in 2.75 mL of thioacetic acid and allowed to stir
at room temperature for 43 h. The thioacetic acid was then evaporated via argon flow and the
residue purified via column chromatography (1:1 Hex:EtOAc) to yield 0.196 g (87% yield) of
product. Rf 0.1 (1:1 Hex:EtOAc). NMR data matches reference 82c. HRMS (ESI-TOF): m/z
[M+H]+cal = 727.3078, [M+H]+obs = 727.3049.
Synthesis of N-(9H-Fluoren-9-ylmethoxycarbonyl-O-(2-acetamido-3,4-di-O-acetyl-2-deoxy6-O-[methyl-(5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy--D-glycero-D-galacto-2nonulopyranosyl)onate]--D-galactopyranosyl)-L-threonine (3)
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Dissolved 46 (147 mgs, 0.127 mmol) in 3.6 mL trifluoroacetic acid and 0.3 mL anisole
and let it stir at room temperature for 1 h. The reaction was then coevaporated with toluene and
chromatographed through silica gel (14:1 to 9:1 to 7:1 DCM:MeOH), yielding 100 mgs of 3
(0.091 mmol, 71% yield). Rf 0.45 (9:1 DCM:MeOH). NMR data matches reference 40a. HRMS
(ESI-TOF): m/z [M+H]+cal = 1102.3880, [M+H]+obs = 1102.3756.
Synthesis of Biotin-NH-(CH2CH2O)2-CH2CH2-NH2 (4)
TFA (0.8 mL) was added dropwise to a solution of Biotin-NH-(CH2CH2O)2-CH2CH2NH-Trt (51, 318 mgs, 0.516 mmol) and triisopropylsilane (0.127 mL, 0.619 mmol) in 23 mL of
dry DCM. The reaction was left to stir at room temperature for 10 min, at which point the acid
was neutralized with NaOMe/MeOH solution until the reaction pH turned to 10. 8 g of washed
and re-activated Amberlyst 15 (left 48 h in MeOH, then filtered, washed with MeOH (x3),
neutralized with ammonium hydroxide (30% in water), re-acidified with 12M HCl, washed with
MeOH (x3), THF (x3), DCM (x3), and finally dried) were added 0.5 g at a time until 4 could no
longer be observed on TLC. The reaction was left stirring with Amberlyst 15 for 2.5 h, at which
point the solution was filtered, washed with MeOH (x3), and the Amberlyst (now containing out
biotin-ethylene glycol-NH3+) was transferred to a large peptide synthesizer. 25 mL of 30% aq
ammonium hydroxide were added and the reaction was left shaking gently for 1 h, at which point
the solvent (now containing our product) was filtered, the amberlyst was washed with water (x3),
and the solvent was frozen and lyophilized. The resulting solid yielded 121 mgs of 4 (0.324
mmol, 63% yield). Rf 0.25 (D:M 1:1). NMR data matches reference 84d. HRMS (ESI-TOF): m/z
[M+H]+cal = 375.2066, [M+H]+obs = 375.1178.
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Solid Phase Peptide Synthesis (5–7)
The photoreactive (glyco)peptides 5-7 were synthesized using standard Fmoc chemistry.
Sieber amide resin with a loadings ranging between 0.65 and 0.69 mmol/g were used. Swelling
of the resin was performed for 10 min in DCM at the beginning of the synthesis. Fmoc removal
was done with 20% piperidine in NMP over 30 min. Coupling of the first amino acid Fmoc-GlyInd(OH) was done with 1.5 equiv. Fmoc-Gly-Ind(OH), 3 equiv. of each HOBt and HBtU, 6
equiv. DIPEA, and enough NMP to dissolve all reagents and maintain good agitation of the
beads during coupling. Loading is usually around 50%, which is desired to prevent aggregation
of the growing (glyco)peptides.
Coupling of Fmoc-amino acids was done with 5 equiv. AA, 5 equiv. HOBt, 5 equiv.
HBtU, and 10 equiv. DIPEA in as little DMF as was necessary for complete dissolution of
reagents and good agitation of the reaction mixture. Coupling was done over 30 min; if a positive
bromophenol blue and/or Kaiser test was observed, a second coupling was done with half the
equivalents of each reagent over 15 min. No third coupling was ever necessary. Capping was
done after every coupling with 10% acetic anhydride and 5% DIPEA in NMP. Glycoamino acid
containing the Tn antigen was coupled for 8 h using 2 equiv. Fmoc-Thr(Ac3AcNH-a-Gal)-OH,
2.4 equiv. HATU, 2.4 equiv. HOAt, and 5 equiv. NMM in NMP (128). Glycoamino acid 3 (STn)
was coupled for 30 min at 50oC with 1.7 equiv. glycoamino acid, 2.5 equiv. HOAt, 2.5 equiv.
HATU, and 5 equiv. NMM in NMP. Terminal amino acid Boc-Arg(Pbf)-OH was used over its
Fmoc derivative to eliminate the possibility of Fmoc removal during prolonged exposure to our
Biotin linker in subsequent photorelease reactions. After peptide synthesis, our photoreactive
(glyco)peptides can be used for photorelease reactions.
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Synthesis of cleaved (glyco)peptides 8-10
For our homogeneous photoreactions, cleavage from Sieber resin is required. Cleavage
from Sieber amide resin is accomplished by shaking resin for 2 min in 1% TFA in DCM (10
mL/g resin). The filtrate is then transferred to a test tube containing 1.2 equiv. (with respect to
TFA) pyridine in MeOH solution (1 mL/g resin). This test tube is kept in an ice bath to reduce
the temperature of the solution and minimize possible -elimination of the sugar on threonine.
These steps are repeated until no more peptide can be observed on TLC. All the fractions are
collected and concentrated. When around 1 mL is left, cold diethyl ether is added, the centrifuge
tube is left in a -50oC freezer for 10 minutes, and then centrifuged. The solvent is decanted and
the remaining pellet is washed twice more with cold diethyl ether. The remaining pellet is then
purified through silica chromatography and its purity is observed by FPLC (0% to 90% solvent
A; Solvent A = 0.1% TFA, 2% CH3CN in water, Solvent B = 0.1% TFA, 85% CH3CN in water),
Peptide 8: RP-FPLC Rt 27.17 min; HRMS (ESI-TOF): m/z [M+H]+cal = 2112.0498, [M+H]+obs =
2112.0489; [M+H-trityl]+cal = 1869.9403, [M+H-trityl]+obs = 1868.9218; [M+2H]2+cal =
1056.5288, [M+H]+obs = 1056.5345; [M+2H-trityl]2+cal = 935.4740, [M+H-trityl]+obs = 935.4715.
Glycopeptide 9: RP-FPLC Rt 26.53 min; HRMS (ESI-TOF): m/z [M+H]+cal = 2385.0983,
[M+H]+obs = 2385.0644; [M+H-trityl]+cal = 2142.9887, [M+H-trityl]+obs = 2142.9818;
[M+2H]2+cal = 1193.0530, [M+H]+obs = 1193.0562.
Glycopeptide 10: RP-FPLC Rt 26.61 min; HRMS (ESI-TOF): m/z [M+H]+cal = 2817.2444,
[M+H]+obs = 2817.1709; [M+2H]2+cal = 1408.6244, [M+H]+obs = 1408.6246.
General Homogeneous – Free Acid Formation Method (11-13)
The photoreactive (glyco)peptide is dissolved in THF/water (90%, 10%, molarity = 0.01)
and photoirradiated with 350 nm light for 4 hours. The reaction is then concentrated and purified
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via either silica chromatography or FPLC (0% to 90% solvent A; Solvent A = 0.1% TFA, 2%
CH3CN in water, Solvent B = 0.1% TFA, 85% CH3CN in water), resulting in (glyco)peptides 1113.
Peptide 11: Yield: 73%; RP-FPLC Rt 27.31 min; HRMS (ESI-TOF): m/z [M+H]+cal =
1922.9960, [M+H]+obs = 1922.9785; [M+K]+cal = 1960.9519, [M+K]+obs = 1960.9519; [M+Htrityl]+cal = 1679.8831, [M+H-trityl]+obs = 1679.8653; [M+Na-trityl]+cal = 1701.8650, [M+Natrityl]+obs = 1703.8633; [M+K-trityl]+cal = 1718.8423, [M+K-trityl]+obs = 1718.8468.
Glycopeptide 12: Yield: 90%; RP-FPLC Rt 26.39 min; HRMS (ESI-TOF): m/z [M+H]+cal =
2196.0445, [M+H]+obs = 2196.0463; [M+H-trityl]+cal = 1952.9316, [M+H-trityl]+obs = 1952.9185;
[M+K-trityl]+cal = 1991.8908, [M+K-trityl]+obs = 1991.8883.
Glycopeptide 13: Yield: 92%; RP-FPLC Rt 26.54 min; HRMS (ESI-TOF): m/z [M+H]+cal =
2627.1872, [M+H]+obs = 2627.2588; [M+H-trityl]+cal = 2385.0777, [M+H-trityl]+obs = 2385.1139;
[M+2H]2+cal = 1314.0975, [M+2H]2+obs = 1314.0939; [M+2H-trityl]2+cal = 1193.0427, [M+2Htrityl]2+obs = 1193.0438.
General Photorelease – Free Acid Formation Method (11-13)
The beads are washed with DCM and thoroughly dried under vacuum. The dried resin is
then weighed and the amount of peptide calculated (weight of dried resin minus weight of resin
used for SPPS). The amount of resin to be used is then calculated based on how much peptide
one expects at the end (normally 10 mgs). The resin is then placed in a 10 mL test tube and a
small stirring bar is added. Solvent is then added (90% THF, 10% water), the test tube capped,
and the beads are then photoirradiated for 15 hours. The reaction is then filtered and the filtrate
concentrated, resulting in (glyco)peptides 11-13 (Yields = 11: 87%; 12: 92% (2 steps); 13: 84%).
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General Homogeneous – Biotinylation Method (14-16)
The photoreactive (glyco)peptide and biotin linker are dried as described for Nhydroxysuccinimide under the biotinylation photorelease method. All other items (Nhydroxysuccinimide, test tube, stirring bar, molecular sieves) are treated as described under the
same photorelease method. Dry THF/DMSO (85%/15%, molarity = 0.01) is used to dissolve and
transfer all reactants into the test tube; Photoreactive (glyco)peptide (1 equiv.), HOSu (3 equiv.),
and biotin linker (1.2 equiv.). The reaction is allowed to stir for 10 min in freshly activated,
ground up 4Ao molecular sieves under argon, then placed in the photoreactor and irradiated for 4
hours. The reaction is then filtered, the filtrate concentrated, and the reaction purified via either
silica chromatography, resulting in (glyco)peptides 14-16. Purity of the compounds is then
checked with RP-FPLC (0% to 90% solvent A; Solvent A = 0.1% TFA, 2% CH3CN in water,
Solvent B = 0.1% TFA, 85% CH3CN in water) and HR-MS.
Peptide 14: Yield: 80%; RP-FPLC Rt 26.61 min; HRMS (ESI-TOF): m/z [M+H]+cal =
2279.1842, [M+H]+obs = 2279.2160; [M+H-trityl]+cal = 2037.0747, [M+H-trityl]+obs = 2037.0637;
[M+2H]2+cal = 1140.0960, [M+H]+obs = 1140.0953.
Glycopeptide 15: Yield: 78%; RP-FPLC Rt 25.82 min; HRMS (ESI-TOF): m/z [M+H]+cal =
2552.2327, [M+H]+obs = 2552.3072; [M+H-trityl]+cal = 2310.1231, [M+H-trityl]+obs = 2310.1097;
[M+2H]2+cal = 1276.6202, [M+2H]2+obs = 1276.6169; [M+2H-trityl]2+cal = 1155.5654, [M+2Htrityl]2+obs = 1155.5688.
Glycopeptide 16: Yield: 79%; RP-FPLC Rt 25.91 min; HRMS (ESI-TOF): m/z [M+2H]2+cal =
1492.1916, [M+H]+obs = 1492.1912; [M+2H-trityl]2+cal = 1371.1368, [M+H-trityl]+obs =
1371.1306.
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General Photorelease – Biotinylation Method (14-16)
The amount of (glyco)peptide on the beads is calculated as discussed previously (10 mgs
peptide, 1 equiv.). Dry benzene is then added to the resin and evaporated. This is repeated
several times to remove any water which may be present on the resin. The same is done with the
biotin linker, plus a final round of dry benzene lyophilization which left the biotin linker as a
“fluffy” material which is more easily managed. N-hydroxysuccinimide is kept on a desiccator
for at least a day, and the test tube and stirring bar to be used are kept in a 160oC oven at least
overnight. Freshly activated and ground up molecular sieves are added to the test tube, followed
by capping and argon flushing of the test tube. The dried beads are then added to the test tube.
The N-hydroxysuccinimide (3 equiv.) and biotin linker (1.2 equiv.) are weighed into a
microcentrifuge tube, dissolved in dry THF/DMSO (85%, 15%), and transferred to the test tube.
The reaction mixture is then allowed to stir for 10 minutes to allow the activated molecular
sieves to do one last round of drying, and the reaction is then placed on the photoreactor and
photoirradiated for 15 hours. The reaction is then filtered and the filtrate concentrated, resulting
in (glyco)peptides 14-16 (Yields = 14: 64%; 15: 67%; 16: 76%).
General Homogeneous – Thioester Formation Method (17-19)
The photoreactive (glyco)peptide and all other reactants/vessels were dried and treated as
described previously. Dry DMF was used to transfer all reactants into the dry test tube (molarity
= 0.05). After drying for 10 minutes in freshly activated, ground up 4Ao molecular sieves under
argon, the reaction was placed in the photoreactor and irradiated for 2 hours. The reaction was
then taken from the photoreactor and 10 equiv. of thiophenol were added. After 2 hours, the
reaction was filtered into a 10 mL centrifuge tube and the peptide was precipitated using diethyl
ether. The resulting pellet was washed twice more with diethyl ether. The peptide is then
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deprotected with TFA/TIS/H2O 15/0.9/0.9 and purified by FPLC, resulting in (glyco)peptides
17-19.
Peptide 17: Yield: 77% (2 steps); RP-FPLC Rt 30.68 min; HRMS (ESI-TOF): m/z [M+H]+cal =
2015.0045, [M+H]+obs = 2014.9912; [M+H-trityl]+cal = 1771.8915, [M+H-trityl]+obs = 1771.8820;
[M+Na-trityl]+cal = 1795.8695, [M+Na-trityl]+obs = 1795.8695.
Glycopeptide 18: Yield: 84% (2 steps); RP-FPLC Rt 29.37 min; HRMS (ESI-TOF): m/z
[M+H]+cal = 2288.0529, [M+H]+obs = 2288.1505; [M+Na]+cal = 2310.0349, [M+H]+obs =
2310.1413; [M+H-trityl]+cal = 2045.9434, [M+H-trityl]+obs = 2045.9498; [M+Na-trityl]+cal =
2067.9253, [M+Na-trityl]+obs = 2067.9274; [M+K-trityl]+cal = 2083.8992, [M+K-trityl]+obs =
2083.9292.
Glycopeptide 19: Yield: 79% (2 steps); RP-FPLC Rt 29.15 min; HRMS (ESI-TOF): m/z
[M+H]+cal = 2720.1990, [M+H]+obs = 2720.1234; [M+2H]2+cal = 1360.6034, [M+2H]2+obs =
1360.6016; [M+2H-trityl]2+cal = 1239.5486, [M+2H-trityl]2+obs = 1239.5471.
General Side Chain Deprotection Method (20-28)
Protected (glyco)peptides are dissolved in a solution containing TFA/TIS/H2O
(15/0.9/0.9) and allowed to stir at room temperature for 2 hours. The peptides are then
precipitated using cold diethyl ether, centrifuged, and the resulting pellet is consecutively washed
with more diethyl ether until TFA is no longer present. The resulting pellet is then purified via
reverse phase FPLC, resulting in (glyco)peptides 20-28.
Peptide 20: Yield: quantitative; RP-FPLC Rt 10.07 min; HRMS (ESI-TOF): m/z [M+H]+cal =
1215.6234, [M+H]+obs = 1215.6190; [M+2H]2+cal = 608.3156, [M+H]+obs = 608.1674.
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Glycopeptide 21: Yield: 92% (2 steps); RP-FPLC Rt 12.69 min; HRMS (ESI-TOF): m/z
[M+H]+cal = 1544.7345, [M+H]+obs = 1544.7241; [M+2H]2+cal = 772.8711, [M+2H]2+obs =
772.8183.
Glycopeptide 22: Yield: 98%; RP-FPLC Rt 14.65 min; HRMS (ESI-TOF): m/z [M+H]+cal =
1976.8806, [M+H]+obs = 1976.8564; [M+2H]2+cal = 988.9442, [M+H]+obs = 988.9446; [M+2Hsugars]2+cal = 608.3156, [M+2H-sugars]2+obs = 608.2094.
Peptide 23: Yield: quantitative; RP-FPLC Rt 12.05 min; HRMS (ESI-TOF): m/z [M+H]+cal =
1571.8117, [M+H]+obs = 1571.8037; [M+2H]2+cal = 786.4097, [M+H]+obs = 786.3868.
Glycopeptide 24: Yield: 97%; RP-FPLC Rt 14.76 min; HRMS (ESI-TOF): m/z [M+H]+cal =
1901.9261, [M+H]+obs = 1901.9340; [M+2H]2+cal = 951.4669, [M+2H]2+obs = 951.4675.
Glycopeptide 25: Yield: 98%; RP-FPLC Rt 15.70 min; HRMS (ESI-TOF): m/z [M+H]+cal =
2333.0688, [M+H]+obs = 2333.0372; [M+2H]2+cal = 1167.0383, [M+2H]2+obs = 1167.0394;
[M+2H-sugars]2+cal = 786.4097, [M+2H-sugars]2+obs = 786.3912.
Peptide 26: Yield: 77% (2 steps); RP-FPLC Rt 13.75 min; HRMS (ESI-TOF): m/z [M+H]+cal =
1307.6319, [M+H]+obs = 1307.6332; [M+2H]2+cal = 654.3198, [M+2H]2+obs = 654.2014.
Glycopeptide 27: Yield: 84% (2 steps); RP-FPLC Rt 16.00 min; HRMS (ESI-TOF): m/z
[M+H]+cal = 1636.7430, [M+H]+obs = 1636.7344; [M+2H]2+cal = 818.8743, [M+H]+obs =
818.8422.
Glycopeptide 28: Yield: 79% (2 steps); RP-FPLC Rt 17.35 min; HRMS (ESI-TOF): m/z
[M+H]+cal = 2068.8891, [M+H]+obs = 2068.8662; [M+2H]2+cal = 1034.9484, [M+2H]2+obs =
1034.9517.
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General Sugar Deprotection Method (29-32)
Glycopeptides 21 and 24 were dissolved in methanol (5 mL) and a solution of NaOMe
was added until the pH reached 10. This solution was stirred at room temperature for 40 hours, at
which point it was neutralized with acetic acid and precipitated with cold diethyl ether. The
glycopeptides were then purified by reverse phase FPLC, resulting in glycopeptides 29 and 30.
Glycopeptides containing the STn antigen (22 and 25) were dissolved in MeOH with 1M
NaOH (1% v/v) and stirred at room temperature for 2.5 hours. The mixture was then neutralized
with 90 mM aq. AcOH to a pH of 6 and evaporated. The glycopeptides were then dissolved in
5mM aq. NaOH and stirred at room temperature for 3 h 45 min. The solution was again
neutralized to a pH of 6 with 90 mM aq. AcOH. The solution was then frozen and lyophilized.
The glycopeptides were then purified by reverse phase FPLC, resulting in glycopeptides 31 and
32
Glycoeptide 29: Yield: 86%; RP-FPLC Rt 10.05 min; HRMS (ESI-TOF): m/z [M+2H]2+cal =
709.8553, [M+2H]2+obs = 709.8558; [M+H+Na]2+cal = 720.8463, [M+H+Na]2+obs = 709.8882.
Glycopeptide 30: Yield: 87%; RP-FPLC Rt 12.35 min; HRMS (ESI-TOF): m/z [M+2H]2+cal =
887.9494, [M+2H]2+obs = 887.9442; [M+H+Na]2+cal = 899.4421, [M+H+Na]2+obs = 899.4398.
Glycopeptide 31: Yield: 78%; RP-FPLC Rt 9.87 min; HRMS (ESI-TOF): m/z [M+2H]2+cal =
855.4030, [M+2H]2+obs = 855.3970; [M+H+Na]2+cal = 866.3940, [M+H+Na]2+obs = 866.3906.
Glycopeptide 32: Yield: 74%; RP-FPLC Rt 12.19 min; HRMS (ESI-TOF): m/z [M+2H]2+cal =
1033.4973, [M+2H]2+obs = 1033.5018; [M+H+Na]2+cal = 1044.9898, [M+H+Na]2+obs =
1044.9942.
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Synthesis of allyl indole-5-carboxylate (34)
Indole-5- carboxylic acid (33) (5.4 g, 33.5 mmol) and cesium carbonate (6.55 g, 20.1
mmol) were dissolved in dry DMF (18 mL) under Argon environment. To this solution, allyl
bromide (29 mL, 335 mmol) was added dropwise over 30 min. The solution was allowed to stir
at room temperature for 2 hours. The DMF was co-evaporated using toluene and the resulting gel
was re-dissolved using ethyl acetate. An aqueous workup was done with water, sodium
bicarbonate, then brine. The organic layer was dried over magnesium sulfate, filtered through
celite, and dried. Product 34 was used as a crude for the following reaction (reduction of allyl
indole-5-carboxylate). Rf 0.6 (1:1 EtOAc:Hex). NMR data matches reference 82. HRMS (ESITOF): m/z [M+H]+cal = 202.0868, [M+H]+obs = 202.0729.
Synthesis of allyl indoline-5-carboxylate (35)
Allyl indole-5-carboxylate (34, crude, 33.5 mmol) was dissolved in acetic acid and
allowed to stir at room temperature for 15 min. The reaction was then placed in an ice bath and
cooled down to 10oC. Sodium cyanoborohydride (10.5 g, 167.5 mmol) was added in small
portions over 10 min. The reaction was then allowed to stir at room temperature over 2 hr. The
reaction was then transferred to a separatory funnel, diluted with ethyl acetate, and an aqueous
workup was performed (water, sodium bicarbonate 5x, brine). The organic layer was then dried
over magnesium sulfate, filtered through celite, and evaporated. The resulting solid 35 was used
as a crude for the next reaction (acetylation of allyl indoline-5-carboxylate). Rf 0.35 (3:1
Hex:Acetone). NMR data matches reference 82.
Synthesis of allyl N-acetylindoline-5-carboxylate (36)
Allyl indoline-5-carboxylate (35, crude, 33.5 mmol) was dissolved in dry DCM.
Triethylamine (7 mL, 50.25 mmol) and acetic anhydride (31.7 mL, 335 mmol) were added and
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the reaction was allowed to stir at room temperature overnight. The reaction was diluted further
with DCM and an aqueous extraction was done (water, sodium bicarbonate 3x, brine). The
organic phase was then dried over magnesium sulfate, filtered through celite, and dried. The
solid was then purified by column chromatography (1:1 Hex:EtOAc). 4.35 g of allyl Nacetylindoline-5-carboxylate (36) (17.74 mmol, 53% yield over 3 steps) were recovered. Rf 0.25
(1:1 Hex:EtOAc); 1H NMR (600 MHz, 23.4 °C, CDCl3, δH) 8.19 (d, J = 8.9 Hz, 1H, ArH), 7.89,
(d, J = 6.9 Hz, 1H, ArH), 7.78 (s, 1H, ArH), 6.03-6.00 (m, 1H, CH2=CH), 5.40-5.38 (dd, 1H,
CH2=CH), 5.28-5.26 (dd, 1H, CH2=CH), 4.78 (d, 2H, CH2-O), 4.04 (t, J = 8.2 Hz, 2H, NCH2),
3.16 (t, J = 8.9 Hz, 2H, NCH2CH2), 2.18 (s, 3H, CH3);

13C

NMR (600 MHz, 23.4 °C, CDCl3,

δC) 169.32, 165.86, 146.91, 132.42, 131.50, 130.08, 125.93, 125.03, 118.10, 115.98, 65.37,
49.12, 27.45, 24.26.
Synthesis of allyl-7-nitro-N-acetylindoline-5-carboxylate (37)
Allyl N-acetylindoline-5-carboxylate (36, 0.2 g, 0.8 mmol) was dissolved in 2.5 mL TFA
and cooled to 0oC. Sodium Nitrate (0.68 g, 8 mmol) was added in 8 portions over 10 min. The
reaction was then brought to room temperature and allowed to stir for 2.5 hr. It was then heavily
diluted with DCM and transferred to a separatory funnel. The organic layer was then extracted
with water, sodium bicarbonate x3, and brine, then dried over magnesium sulfate, filtered
through celite, and concentrated. The resulting solid was then purified by column
chromatography (3:1 Hex:Acetone), yielding 0.164 g (71% yield) of 37. Rf 0.25 (1:1
Hex:Acetone); 1H NMR (600 MHz, 23.4 °C, CDCl3, δH) 8.31 (s, 1H, ArH), 8.05 (s, 1H, ArH),
6.06-5.99 (m, 1H, CH2=CH), 5.42 (dd, J = 4.1 Hz, 19.0 Hz, 1H, CH2=CH), 5.33 (dd, J = 1.4 Hz,
10.2 Hz, 1H CH2=CH), 4.83 (d, J = 6.9 Hz, 2H, CH2CH=CH2), 4.31 (t, J = 8.2 Hz, 2H, NCH2),
3.30 (t, J = 8.2 Hz, 2H, NCH2CH2), 2.28 (s, 3H, CH3).
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Synthesis of Fmoc-Gly-Ind(OAll) (38)
Allyl 7-nitro-N-acetylindoline-5-carboxylate (37), 0.159 g, 0.548 mmol) in wet
acetonitrile (20 mL), placed the round bottom in a water circulator inside the UV reactor, and
illuminated the reaction with 350 nm light for 7.5 h. The acetonitrile was then evaporated and the
resulting solid was purified by column chromatography (1:1 Hex:EtOAc). 0.088 g (65% yield) of
product 38 were recovered. Rf 0.35 (3:1 Hex:Acetone) 1H NMR (600 MHz, 23.4 °C, CDCl3, δH)
8.57 (s, 1H, ArH), 7.80 (s, 1H, ArH), 7.12 (br s, 1H, NH), 6.06-5.99 (m, 1H, CH2=CH), 5.41
(dd, J = 1.4 Hz, J = 17.1 Hz, 1H, CH2=CH), 5.30 (dd, J = 1.4 Hz, J = 10.3 Hz, 1H, CH2=CH),
4.79 (d, J = 5.5 Hz, 2H, CH2CH=CH2), 3.99 (t, J = 8.2 Hz, 2H, NCH2), 3.24 (t, J = 8.9 Hz, 2H,
NCH2CH2).
Synthesis of Fmoc-Gly-Ind(OAll) (39)
In a dried and argon flushed round bottom, Fmoc-Gly-OH (0.39 g, 1.313 mmol) was
dissolved in dry DCM. Trichloroacetonitrile (0.304 mL, 3.03 mmol) was then added, followed
by freshly recrystallized triphenylphosphine (0.795 g, 3.03 mmol). Bubble formation is observed
at this point, as well as subsequent dissolution of the amino acid and a color change to light
yellow. After 15 min, allyl 7-nitro-1-H-indoline-5-carboxylate (35, 0.25 g, 1.01 mmol) was
added, a reflux condenser was installed, and the reaction was allowed to stir at 40oC for 17 h.
DCM was then evaporated and the solid mixture was dry loaded for column chromatography to
get rid of excess triphenylphosphine. Note that both the desired product and the byproduct
triphenylphosphine oxide have a near identical Rf value, so complete separation through column
chromatography was not accomplished. This still crude mixture was used as-is for the
subsequent de-allylation reaction. Rf 0.1 (3:1 Hex:Acetone).
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Synthesis of 3,4,6-Tri-O-acetyl-2-azido-2-deoxy--D-galactopyranosyl bromide (41)
In a dried and argon flushed round bottom flask, 40 (0.5 g, 1.34 mmol) was dissolved in
dry DCM (12 mL). TiBr4 (1.33 g, 3.62 mmol) was added, the reaction was brought to a reflux
(40oC) and allowed to stir for 15 h. The reaction was diluted with DCM and worked up with
water, twice sodium bicarbonate, and lastly brine. The organic layer was dried over magnesium
sulfate, filtered through celite, and concentrated. The yield was quantitative. Rf 0.2 (3:1
Hex:EtOAc). NMR data matches reference 82a.
Synthesis of N-(9-Fluorenylmethoxycarbonyl)-O-(3,4,6-tri-O-acetyl-2-azido-2-deoxy--Dgalactopyranosyl)-L-threonine tertbutyl ester (42)
In a dried, argon flushed round bottom, a solution of Fmoc-Thr(OH)-OtBu (0.524 g, 1.32
mmol) in dry toluene (3.8 mL) and dry DCM (6.3 mL) was stirred for 30 min at 0oC under argon
in the dark with 4Ao molecular sieves (0.95g) and silver carbonate (0.437 g, 1.58 mmol). Silver
perchlorate (0.041 g, 0.198 mmol) was then added in dry toluene (1.9 mL) and stirred for 20 min.
A solution of 41 (0.524 g, 1.32 mmol) in dry DCM (5.7 mL) and dry toluene (5.7 mL) was added
dropwise over 40 min. The reaction was then brought to room temperature and allowed to stir for
10 h. A workup was avoided; the solvents were evaporated and the resulting solid was purified
by column chromatography (2:1 Hex:EtOAc). The yield was 60%. Rf 0.25 (2:1 Hex:EtOAc).
NMR data matches reference 82b. HRMS (ESI-TOF): m/z [M+Na]+cal = 733.2697, [M+H]+obs =
733.2629.
Synthesis of N-(9-Fluorenylmethoxycarbonyl)-O-(2-acetamido-2-deoxy--Dgalactopyranosyl)-L-threonine tertbutyl ester (43)
In a dried and argon flushed round bottom, Fmoc-Thr(-Ac3GalNAc)-OtBu (2, 0.46 g,
0.633 mmol) was dissolved in 9 mL dry MeOH. 3 mL of fresh NaOMe/MeOH solution (pH 10)
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were added and the reaction was stirred at room temperature for 3.5 h. Amberlyst was added, the
reaction was stirred for 5 minutes, and the amberlyst was then filtered through Celite. The
reaction was then concentrated and chromatographed (9:1 DCM:MeOH) yielding 0.297 g (78%
yield) of product 40. Rf 0.25 (9:1 DCM:MeOH). NMR data matches reference 83a.
Synthesis of 5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy--2-O-Acetyl Neuraminic
Acid Methyl Ester (45)
In a dried and argon flushed round bottom was dissolved N-acetylneuraminic acid (44,
0.5 g, 1.62 mmol) in dry MeOH (25 mL). Amberlyst 15 (2.5 g) was added and the reaction was
allowed to stir at room temperature for 1 h. The reaction was filtered through Celite,
concentrated, and used crude for the following reaction (acetylation). Rf 0.3 (9:1 DCM:MeOH).
5-acetamido-neuraminic acid methyl ester (crude, 1.62 mmol) was dissolved in acetic
anhydride (5 mL) and pyridine (5 mL) and left to stir at room temperature overnight. Methanol
was then added to the reaction to break down excess acetic anhydride and left to stir for 5 min.
The reaction was then co-evaporated with toluene until most of the pyridine was gone, at which
point the reaction was diluted with EtOAc and Amberlyst 15 was added to help trap any pyridine
still left. 45 was then filtered through celite, concentrated, and chromatographed: Rf 0.2 (1:7
Hex:EtOAc). Quantitative yield. NMR data matches reference 83b.
Synthesis of 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy--2-Chloro Neuraminic Acid
Methyl Ester (46)
5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy--2-O-Acetyl Neuraminic Acid
Methyl Ester (45, 0.579 g, 1.09 mmol) was dissolved in 10 mL AcCl and left to stir at room
temperature for 64 h. Some starting material could still be observed, so the AcCl was coevaporated using toluene and fresh AcCl (10 mL) was added to the reaction and left to stir at
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room temperature for another 68 h. This was then co-evaporated with toluene and dried until no
traces of acid could be observed, then used crude for the next reaction (Xanthate activation). Rf
0.33 (1:7 Hex:EtOAc). NMR data matches reference 83c
Synthesis of O-Ethyl-S-[methyl (5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy--Dglycero-D-galacto-2-nonulopyranosyl)onate] thiocarbonate (47)
In a dried and argon flushed round bottom, 46 (crude, 1.09 mmol) was dissolved in dry
ethanol and left to stir in the dark at room temperature for 23 h. The reaction was then diluted
with DCM and an aqueous workup was done (water 2x, brine 1x). The organic layer was dried
over magnesium sulfate, filtered through celite, and concentrated. Silica chromatography was
done (1:7 Hex:EtOAc) and 0.424 g of product 47 (.713 mmol, 65% yield over two steps) was
recovered. Rf 0.23 (1:7 Hex:EtOAc). NMR data matches reference 83c. HRMS (ESI-TOF): m/z
[M+K]+cal = 634.1030, [M+K]+obs = 634.1011.
Synthesis of N-(9H-Fluoren-9-ylmethoxycarbonyl-O-(2-acetamido-2-deoxy-6-O-[methyl-(5acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy--D-glycero-D-galacto-2nonulopyranosyl)onate]--D-galactopyranosyl)-L-threonine tert-butyl ester (48)
In a dried and argon flushed round bottom flask, Fmoc-Thr(-GalNAc)-OtBu (43, 0.183
g, 0.305 mmol) and 47 (0.471 g, 0.793 mmol) were dissolved in 10.5 mL dry CH3CN/CH2Cl2
(2:1). 0.75 g 4Ao molecular sieves were added and the mixture was stirred at room temperature
for 1 h. The round bottom was then covered in aluminum foil and cooled to -65oC. Silver triflate
(0.204 g, 0.793 mmol) was added in the dark. Methylsulfenyl bromide [MSB, prepared
separately in a dried, argon flushed round bottom by adding Br2 (205 uL, 4mmol) to a solution of
dimethyl disulfide (355 uL, 4 mmol) in 1,2-dichloroethane (5 mL) and letting it stir overnight
under exclusion of oxygen and light at 0oC] was added dropwise over 20 min.
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After 3.5 h, Diisopropylethylamine (0.27 mL) was added and the reaction stirred another
15 min. The reaction was then allowed to come to room temperature, diluted with DCM and
filtered through celite. The filtrate was concentrated and chromatographed through silica gel
(19:1 DCM:MeOH), yielding 181 mgs of 48 (0.168 mmol, 55% yield). Rf 0.1 (19:1
DCM:MeOH). NMR data matches reference 40a. HRMS (ESI-TOF): m/z [M+H]+cal =
1074.4294, [M+H]+obs = 1074.4458.
Synthesis of N-(9H-Fluoren-9-ylmethoxycarbonyl-O-(2-acetamido-3,4-di-O-acetyl-2-deoxy6-O-[methyl-(5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy--D-glycero-D-galacto-2nonulopyranosyl)onate]--D-galactopyranosyl)-L-threonine tert-butyl ester (49)
48 (179 mgs, 0.166 mmol) was dissolved in pyridine (7 mL) and then cooled to 0oC.
Acetic anhydride (3.5 mL) was added and the reaction was left to stir at room temperature for 17
h. The reaction was then coevaporated with toluene (x3) and chromatographed through silica gel
(EtOAc), yielding 150 mgs of 3 (0.129 mmol, 78% yield). Rf 0.18 (EtOAc). NMR data matches
reference 40a. HRMS (ESI-TOF): m/z [M+H]+cal = 1158.4506, [M+H]+obs = 1158.4494.
Synthesis of Biotin-Pentafluorophenyl Ester (51)
A mixture of Biotin (50, 510 mgs, 2.09 mmol), 2,3,4,5,6-pentafluorophenol (500 mgs,
2.72 mmol), and EDCI (1 g, 5.225 mmol) was stirred for 21 h at room temperature in 15 mL of
acetonitrile. The solvent was evaporated and the resulting mixture chromatographed through
silica gel (19:1 DCM:MeOH), yielding 0.74 g (1.8 mmol, 86% yield) of activated
pentafluorophenolic ester of biotin (51). Rf 0.2 (19:1 DCM:MeOH). NMR data matches
reference 84a. HRMS (ESI-TOF): m/z [M+H]+cal = 411.0802, [M+H]+obs = 411.0458.
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Synthesis of Trt-NH-(CH2CH2O)2-CH2CH2-NH2 (53)
A solution of chlorotriphenylmethane (237 mgs, .851 mmol) in 3.15 mL of DCM was
added dropwise over 15 min to a solution containing 2,2’-(ethylene-dioxy)bis(ethylamine) (52,
1.24 mL, 8.51 mmol) in 6.3 mL DCM. A TLC was taken immediately following Trt-Cl addition
and was considered to be done. The reaction was diluted with DCM and an aqueous workup
(H2O x5) was done, the organic layered dried over magnesium sulfate, filtered through celite,
and evaporated. The resulting crude was used for the next reaction. Rf 0.28 (7:2 DCM:MeOH).
NMR data matches reference 84b.
Synthesis of Biotin-NH-(CH2CH2O)2-CH2CH2-NH-Trt (54)
A solution of biotin-pentafluorophenyl ester (51, 384 mgs, 0.936 mmol) in 10 mL dry
DMF was added to a solution of Trt-NH-(CH2CH2O)2-CH2CH2-NH2 (53, crude, 0.851 mmol)
and triethylamine (0.13 mL, 0.936 mmol) in 5 mL dry DMF. This mixture was allowed to stir at
room temperature for 90 min. DMF was then co-evaporated with toluene and chromatographed
through silica gel (15:1 to 9:1 DCM:MeOH), yielding 424 mgs (0.687 mmol, 81% yield over 2
steps) of product 54. Rf 0.25 (9:1 DCM:MeOH). NMR data matches reference 84c. HRMS (ESITOF): m/z [M+H]+cal = 617.3162, [M+H]+obs = 617.1964.
.
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Abbreviations
AA
AcCl
Ala
AML
Bn
Bni
Boc
DCC
DCM
DIC
DIPEA
DMF
DMSO
DNA
EDCI
EGF
Eq
ER
FDA
Fmoc
FPLC
Fuc
Gal
GalNAc
Glc
GlcA
GlcNAc
Gly
HATu
HBTu
HCl
HF
HOAt
HOBt
IdoA
Kd
LC

Amino Acid

Acetyl Chloride
Alanine

Auxiliary Mediated Ligation
Benzyl

5-Bromo-7-nitroindoline
tert-Butyloxycarbonyl

N,N’dicyclohexylcarbodiimide
Dichloromethane
N,N’-diisopropylcarbodiimide
Diisopropylethylamine
Dimethylformamide
Dimethylsulfoxide
Deoxyribonucleic Acid
N-(3-Dimethylaminopropyl)-N'-ethylcarbociimide hydrochloride

Epidermal Growth Factor
Equivalent(s)

Endoplasmic Reticulum
Food and Drug Administration
fluorenylmethyloxycarbonyl

Fast Protein Liquid Chromatography
Fucose
Galactose
N-Acetylgalactosamine
Glucose
Glucuronic Acid
N-Acetylglucosamine
Glycine

(N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridine-1-ylmethylene]-Nmethylmethanaminium hexafluorophosphate-N-oxide
N,N,N’,N’-tetramethyl-O-(1H-benzotriazol-1-yl)uranium
hexafluorophosphate
Hydrochloric Acid
Hydrofluoric Acid

1-hydroxy-7-azabenzotriazole
1-hydroxy-benzotriazole
Iduronic Acid
Dissociation Constant
Long Chain
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Leu
M
MAM
Man
MSB
MUC
MUC1
N
NCL
NHS
NMM
NMP
Nu
Pbf
PEG
PG
PS
PyBOP
Rf
SA
SPG
SPPS
SPS
TBTU
tBu/t-Bu
TEA
TFA
THF
TIS
TLC
Trt
UV
Val
Xyl

Leucine

Molar
Membrand Anchored Mucin
Mannose
Methylsulfenyl Bromide
Mucin
Mucin 1
Alpha Nitrogen

Native Chemical Ligation
N-hydroxysuccinimide
N-methylmorpholine
N-methyl-2-pyrrolidone
Nucleophile
pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl
polyethylene glycol
Protecting Group

polystyrene
benzotriazol-1-yloxytri(pyrrolidino)phosphonium hexafluorophosphate
Retention Factor
Sialic Acid
Side Chain Protecting Group
Solid Phase Peptide Synthesis
solution phase chemistry

(N-[(1H-benzotriazol-1-yl)(dimethylamino)methylene]-Nmethylmethanaminium tetrafluoroborate-N-oxide
tert-Butyl

Triethylamine
Trifluoroacetic Acid

Tetrahydrofuran
Triisopropylsilane
Thin Layer Chromatography
trityl

Ultraviolet
Valine

Xylose
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Supplementary Material (NMR, MS, FPLC)
1

H of Fmoc-Gly-Ind(OH) (1)

69

MS of Fmoc-Gly-Ind(OH) (1)

70

Mass Spectrum of N-(9-Fluorenylmethoxycarbonyl)-O-(3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-D-galactopyranosyl)-L-threonine tertbutyl ester (2)

71

Mass Spectrum of N-(9H-Fluoren-9-ylmethoxycarbonyl-O-(2-acetamido-3,4-di-O-acetyl-2deoxy-6-O-[methyl-(5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy--D-glycero-D-galacto-2nonulopyranosyl)onate]--D-galactopyranosyl)-L-threonine (3)

72

Mass Spectrum of Biotin-ethylene glycol-NH2 (4)

73

MUC1 Peptide 8

Rt (retention time): 27.17 min.

74

MUC1 Peptide 8, min 27.17

HRMS (ESI-TOF): m/z [M+H]+cal = 2112.0498, [M+H]+obs = 2112.0489; [M+H-trityl]+cal =
1869.9403, [M+H-trityl]+obs = 1868.9218; [M+2H]2+cal = 1056.5288, [M+H]+obs = 1056.5345;
[M+2H-trityl]2+cal = 935.4740, [M+H-trityl]+obs = 935.4715.

75

MUC1 Glycopeptide (Tn) 9

Rt: 26.53 min.

76

MUC1 Glycopeptide (Tn) 9, min 26.53

HRMS (ESI-TOF): m/z [M+H]+cal = 2385.0983, [M+H]+obs = 2385.0644; [M+H-trityl]+cal =
2142.9887, [M+H-trityl]+obs = 2142.9818; [M+2H]2+cal = 1193.0530, [M+H]+obs = 1193.0562.

77

MUC1 Glycopeptide (STn) 10

Rt: 26.61 min.

78

MUC1 Glycopeptide (STn) 10, min 26.61

HRMS (ESI-TOF): m/z [M+H]+cal = 2817.2444, [M+H]+obs = 2817.1709; [M+2H]2+cal =
1408.6244, [M+H]+obs = 1408.6246.

79

MUC1 Peptide Homogeneous Photoreaction: Free Acid 11, post-chromatography

Rt: 27.31 min.

80

MUC1 Peptide Homogeneous Photoreaction: Free Acid 11, min 27.3

HRMS (ESI-TOF): m/z [M+H]+cal = 1922.9960, [M+H]+obs = 1922.9785; [M+K]+cal =
1960.9519, [M+K]+obs = 1960.9519; [M+H-trityl]+cal = 1679.8831, [M+H-trityl]+obs = 1679.8653;
[M+Na-trityl]+cal = 1701.8650, [M+Na-trityl]+obs = 1703.8633; [M+K-trityl]+cal = 1718.8423,
[M+K-trityl]+obs = 1718.8468.

81

MUC1 Peptide Photorelease: Free Acid 11, Crude

Rt: 27.21 min.

82

MUC1 Peptide Photorelease: Free Acid 11, post-chromatography

Rt: 27.33 min.

83

MUC1 Peptide Photorelease: Free Acid 11, min 27.2

HRMS (ESI-TOF): m/z [M+H]+cal = 1922.9960, [M+H]+obs = 1922.9785; [M+K]+cal =
1960.9519, [M+H]+obs = 1960.9490; [M+H-trityl]+cal = 1679.8831, [M+H-trityl]+obs = 1679.8563.

84

MUC1 Glycopeptide (Tn) Homogeneous Photoreaction: Free Acid 12, Crude

Rt: 26.58 min.

MUC1 Glycopeptide (Tn) Homogeneous Photoreaction: Free Acid 12, min 26.58
85

HRMS (ESI-TOF): m/z [M+H]+cal = 2196.0445, [M+H]+obs = 2196.0761; [M+H-trityl]+cal =
1952.9316, [M+H-trityl]+obs = 1952.9190; [M+2H]2+cal = 1098.5261, [M+2H]2+obs = 1098.5274.

MUC1 Glycopeptide (Tn) Photorelease: Free Acid 12, Crude
86

Rt: 26.39 min.

MUC1 Glycopeptide (Tn) Photorelease: Free Acid 12, min 26.39
87

HRMS (ESI-TOF): m/z [M+H]+cal = 2196.0445, [M+H]+obs = 2196.0463; [M+H-trityl]+cal =
1952.9316, [M+H-trityl]+obs = 1952.9185; [M+K-trityl]+cal = 1991.8908, [M+K-trityl]+obs =
1991.8883.

MUC1 Glycopeptide (STn) Homogeneous Photoreaction: Free Acid 13, Crude
88

Rt: 26.67 min.

MUC1 Glycopeptide (STn) Photorelease: Free Acid 13, Crude
89

Rt: 26.54 min.

MUC1 Glycopeptide (STn) Photorelease: Free Acid 13, min. 26.54
90

HRMS (ESI-TOF): m/z [M+H]+cal = 2627.1872, [M+H]+obs = 2627.2588; [M+H-trityl]+cal =
2385.0777, [M+H-trityl]+obs = 2385.1139; [M+2H]2+cal = 1314.0975, [M+2H]2+obs = 1314.0939;
[M+2H-trityl]2+cal = 1193.0427, [M+2H-trityl]2+obs = 1193.0438.

MUC1 Peptide Homogeneous Photoreaction: Biotinylation, 14, post-chromatography
91

Rt: 26.61 min.

MUC1 Peptide Homogeneous Photoreaction: Biotinylation, 14, min 26.6
92

HRMS (ESI-TOF): m/z [M+H]+cal = 2279.1842, [M+H]+obs = 2279.2160; [M+H-trityl]+cal =
2037.0747, [M+H-trityl]+obs = 2037.0637; [M+2H]2+cal = 1140.0960, [M+H]+obs = 1140.0953.

MUC1 Peptide Photorelease: Biotinylion, 14, post-chromatography
93

Rt: 25.72 min, 26.47 min (conformers).

MUC1 Peptide Photorelease: Biotinylation, 14, conformer study, 6 days in NMP
94

Rt: 25.55 min, 26.77 min (conformers).

MUC1 Peptide Photorelease: Biotinylation, 14, min 26.6
95

HRMS (ESI-TOF): m/z [M+H]+cal = 2279.1842, [M+H]+obs = 2279.1424; [M+H-trityl]+cal =
2037.0747, [M+H-trityl]+obs = 2037.0541; [M+2H]2+cal = 1140.0960, [M+H]+obs = 1140.0942;
[M+2H-trityl]2+cal = 1019.0412, [M+H-trityl]+obs = 1019.0405.

MUC1 Glycopeptide (Tn) Homogeneous Photoreaction: Biotinylated 15, crude
96

Rt: 25.82 min; nitroindoline at 15.10 min.

MUC1 Glycopeptide (Tn) Homogeneous Photoreaction: Biotinylated 15, min 25.82
97

HRMS (ESI-TOF): m/z [M+H]+cal = 2552.2327, [M+H]+obs = 2552.3072; [M+H-trityl]+cal =
2310.1231, [M+H-trityl]+obs = 2310.1097; [M+2H]2+cal = 1276.6202, [M+2H]2+obs = 1276.6169;
[M+2H-trityl]2+cal = 1155.5654, [M+2H-trityl]2+obs = 1155.5688.

MUC1 Glycopeptide (Tn) Photorelease: Biotinylated 15, Crude
98

Rt: 25.18 min, 26.03 min (conformers).

MUC1 Glycopeptide (Tn) Photorelease: Biotinylated 15, conformer study, in NMP for 7 days
99

Rt: 25.21 min, 26.26 min (conformers).

MUC1 Glycopeptide (Tn) Photorelease: Biotinylated 15, min 26
100

HRMS (ESI-TOF): m/z [M+H]+cal = 2552.2327, [M+H]+obs = 2552.2585; [M+H-trityl]+cal =
2310.1231, [M+H-trityl]+obs = 2310.1158; [M+2H]2+cal = 1276.6202, [M+2H]2+obs = 1276.6144;
[M+2H-trityl]2+cal = 1155.5654, [M+2H-trityl]2+obs = 1155.5672.

MUC1 Glycopeptide (STn) Homogeneous Photoreaction: Biotinylated 16, Pure
101

Rt: 25.91 min.

MUC1 Glycopeptide (STn) Photorelease: Biotinylated 16, Crude
102

Rt: 25.83 min.

MUC1 Glycopeptide (STn) Photorelease: Biotinylated 16, min. 25.83
103

HRMS (ESI-TOF): m/z [M+2H]2+cal = 1492.1916, [M+H]+obs = 1492.1912; [M+2H-trityl]2+cal =
1371.1368, [M+H-trityl]+obs = 1371.1306.

MUC1 Peptide one-pot-two-reaction procedure: Thioester 17, crude
104

Rt: 30.68 min. Disulfide of thiophenol at 41.78 min.

MUC1 Peptide one-pot-two-reaction procedure: Thioester 17, min 30.68
105

HRMS (ESI-TOF): m/z [M+H]+cal = 2015.0045, [M+H]+obs = 2014.9912; [M+H-trityl]+cal =
1771.8915, [M+H-trityl]+obs = 1771.8820; [M+Na-trityl]+cal = 1795.8695, [M+Na-trityl]+obs =
1795.8695.

MUC1 Glycopeptide (Tn) Homogeneous Photoreaction: Thioester 18, crude
106

Rt: 29.37 min, nitroindoline at 14.99 min, disulfide of thiophenol at 40.27 min.

MUC1 Glycopeptide (Tn) Homogeneous Photoreaction: Thioester 18, min 29.55
107

HRMS (ESI-TOF): m/z [M+H]+cal = 2288.0529, [M+H]+obs = 2288.1505; [M+Na]+cal =
2310.0349, [M+H]+obs = 2310.1413; [M+H-trityl]+cal = 2045.9434, [M+H-trityl]+obs = 2045.9498;
[M+Na-trityl]+cal = 2067.9253, [M+Na-trityl]+obs = 2067.9274; [M+K-trityl]+cal = 2083.8992,
[M+K-trityl]+obs = 2083.9292.

108

MUC1 Glycopeptide (STn) One-Pot-Two Reaction Procedure: Thioester 19, after ether
precipitation

Rt: 29.15 min.

109

MUC1 Glycopeptide (STn) One-Pot-Two Reaction Procedure: Thioester 19, min 29.15

HRMS (ESI-TOF): m/z [M+H]+cal = 2920.1990, [M+H]+obs = 2920.1234; [M+2H]2+cal =
1360.6034, [M+2H]2+obs = 1360.6016; [M+2H-trityl]2+cal = 1239.5486, [M+2H-trityl]2+obs =
1239.5471.

110

MUC1 Peptide: Free Acid 20, Deprotected

Rt: 10.07 min.

111

MUC1 Peptide: Free Acid 20, Deprotected, min 10.07

HRMS (ESI-TOF): m/z [M+H]+cal = 1215.6234, [M+H]+obs = 1215.6190; [M+2H]2+cal =
608.3156, [M+H]+obs = 608.1674.

112

MUC1 Glycopeptide (Tn): Free Acid 21, deprotected side chain

Rt: 12.69 min.

113

MUC1 Glycopeptide (Tn): Free Acid 21, min. 12.69

HRMS (ESI-TOF): m/z [M+H]+cal = 1544.7345, [M+H]+obs = 1544.7241; [M+2H]2+cal =
772.8711, [M+2H]2+obs = 772.8183.

114

MUC1 Glycopeptide (STn): Free Acid 22, deprotected side chain, pure

Rt: 14.65 min.

115

MUC1 Glycopeptide (STn): Free Acid 22, deprotected, min 14.65

HRMS (ESI-TOF): m/z [M+H]+cal = 1976.8806, [M+H]+obs = 1976.8564; [M+2H]2+cal =
988.9442, [M+H]+obs = 988.9446; [M+2H-sugars]2+cal = 608.3156, [M+2H-sugars]2+obs =
608.2094.

116

MUC1 Peptide: Biotinylation, 23, deprotected

Rt: 12.05 min.

117

MUC1 Peptide: Biotinylation, 23, deprotected, min 12.05

HRMS (ESI-TOF): m/z [M+H]+cal = 1571.8117, [M+H]+obs = 1571.8037; [M+2H]2+cal =
786.4097, [M+H]+obs = 786.3868.

118

MUC1 Glycopeptide (Tn): Biotinylated 24, deprotected side chain, pure

Rt: 14.76 min.

119

MUC1 Glycopeptide (Tn): Biotinylated 24, deprotected, min 14.76

HRMS (ESI-TOF): m/z [M+H]+cal = 1901.9261, [M+H]+obs = 1901.9340; [M+2H]2+cal =
951.4669, [M+2H]2+obs = 951.4675.

120

MUC1 Glycopeptide (STn): Biotinylated 25, deprotected side chain, pure

Rt: 15.70 min.

121

MUC1 Glycopeptide (STn): Biotinylated 25, deprotected, min 15.70

HRMS (ESI-TOF): m/z [M+H]+cal = 2333.0688, [M+H]+obs = 2333.0372; [M+2H]2+cal =
1167.0383, [M+2H]2+obs = 1167.0394; [M+2H-sugars]2+cal = 786.4097, [M+2H-sugars]2+obs =
786.3912.

122

MUC1 Peptide: Thioester 26, deprotected, after purification

Rt: 13.75 min.

123

MUC1 Peptide one-pot-two-reaction procedure: Thioester 26, after deprotection, min 13.75

HRMS (ESI-TOF): m/z [M+H]+cal = 1307.6319, [M+H]+obs = 1307.6332; [M+2H]2+cal =
654.3198, [M+2H]2+obs = 654.2014.

124

MUC1 Glycopeptide (Tn): Thioester 27, deprotected, after purification

Rt: 16.00 min.

125

MUC1 Glycopeptide (Tn) Homogeneous Photoreaction: Thioester 27, deprotected, after
purification

HRMS (ESI-TOF): m/z [M+H]+cal = 1636.7430, [M+H]+obs = 1636.7344; [M+2H]2+cal =
818.8743, [M+H]+obs = 818.8422.

126

MUC1 Glycopeptide (STn): Thioester 28, deprotected, pure

Rt: 17.35 min.

127

MUC1 Glycopeptide (STn): Thioester 28, deprotected, min 17.35

HRMS (ESI-TOF): m/z [M+H]+cal = 2068.8891, [M+H]+obs = 2068.8662; [M+2H]2+cal =
1034.9484, [M+2H]2+obs = 1034.9517.

128

MUC1 Glycopeptide (Tn): Free Acid 29, fully deprotected

Rt: 10.05 min.

129

MUC1 Glycopeptide (Tn): Free Acid 29, fully deprotected, min 10.05

HRMS (ESI-TOF): m/z [M+2H]2+cal = 709.8553, [M+2H]2+obs = 709.8558; [M+H+Na]2+cal =
720.8463, [M+H+Na]2+obs = 709.8882.

130

MUC1 Glycopeptide (Tn): Biotinylated 30, fully deprotected

Rt: 12.35 min.

131

MUC1 Glycopeptide (Tn): Biotinylated 30, fully deprotected, min. 12.35

HRMS (ESI-TOF): m/z [M+2H]2+cal = 887.9494, [M+2H]2+obs = 887.9442; [M+H+Na]2+cal =
899.4421, [M+H+Na]2+obs = 899.4398.

132

MUC1 Glycopeptide (STn): Free Acid 31, fully deprotected, pure

Rt: 9.87 min.

133

MUC1 Glycopeptide (STn): Free Acid 31, fully deprotected, min. 9.87

HRMS (ESI-TOF): m/z [M+2H]2+cal = 855.4030, [M+2H]2+obs = 855.3970; [M+H+Na]2+cal =
866.3940, [M+H+Na]2+obs = 866.3906.

134

MUC1 Glycopeptide (STn): Biotinylated 32, fully deprotected, pure

Rt: 12.19 min.

135

MUC1 Glycopeptide (STn): Biotinylated 32, fully deprotected, min. 12.19

HRMS (ESI-TOF): m/z [M+2H]2+cal = 1033.4973, [M+2H]2+obs = 1033.5018; [M+H+Na]2+cal =
1044.9898, [M+H+Na]2+obs = 1044.9942.

136

1

H NMR of allyl indole-5-carboxylate (34)

137

Mass Spectrum of allyl indole-5-carboxylate (34)

138

1

H NMR of allyl N-acetylindoline-5-carboxylate (36)

139

13

C NMR of allyl N-acetylindoline-5-carboxylate (36)

140

1

H NMR of allyl N-acetylnitroindoline-5-carboxylate (37)

141

1

H NMR of allyl 7-nitro-1-H-indoline-5-carboxylate (38)

142

13

C NMR of allyl 7-nitro-1-H-indoline-5-carboxylate (38)

143

1

H NMR of Fmoc-Gly-Ind(OAll) (39)

144

13

C NMR of Fmoc-Gly-Ind(OAll) (39)

145

Mass Spectrum for Fmoc-Gly-Ind(OAll) (39)
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1

H NMR of 3,4,6-Tri-O-acetyl-2-azido-2-deoxy--D-galactopyranosyl bromide (41)

147

13

C NMR 3,4,6-Tri-O-acetyl-2-azido-2-deoxy--D-galactopyranosyl bromide (41)

148

1

H of N-(9-Fluorenylmethoxycarbonyl)-O-(3,4,6-tri-O-acetyl-2-azido-2-deoxy--Dgalactopyranosyl)-L-threonine tertbutyl ester (42)

149

13

C NMR of N-(9-Fluorenylmethoxycarbonyl)-O-(3,4,6-tri-O-acetyl-2-azido-2-deoxy--Dgalactopyranosyl)-L-threonine tertbutyl ester (42)

150

Mass Spectrum of N-(9-Fluorenylmethoxycarbonyl)-O-(3,4,6-tri-O-acetyl-2-azido-2-deoxy--Dgalactopyranosyl)-L-threonine tertbutyl ester (42)

151

Mass Spectrum of O-Ethyl-S-[methyl (5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy--Dglycero-D-galacto-2-nonulopyranosyl)onate] thiocarbonate (47)

152

Mass Spectrum of N-(9H-Fluoren-9-ylmethoxycarbonyl-O-(2-acetamido-2-deoxy-6-O[methyl(5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy--D-glycero-D-galacto-2nonulopyranosyl)onate]--D-galactopyranosyl)-L-threonine tert-butyl ester (48)

153

Mass Spectrum of N-(9H-Fluoren-9-ylmethoxycarbonyl-O-(2-acetamido-3,4-di-O-acetyl-2deoxy-6-O-[methyl-(5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy--D-glycero-D-galacto-2nonulopyranosyl)onate]--D-galactopyranosyl)-L-threonine tert-butyl ester (49)

154

Mass Spectrum of Biotin PFP ester (51)

155

Mass Spectrum of Biotin-ethylene glycol-NHTrt (54)
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